[
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on metastatic breast cancer. The drug being tested is capecitabine. The eligibility criteria include having a functional ECOG status of less than 2, having at least one measurable lesion according to RECIST criteria, and having a life expectancy of at least 3 months. There are also exclusion criteria, such as having previously shown severe reactions to therapy with fluoropyrimidines or having severe intellectual impairment.",
    "The sample is a clinical trial for gastroesophageal reflux disease, with a phase 2/phase 3 designation. The trial involves testing the effectiveness of different doses and combinations of the drug rabeprazole, along with a placebo, for treating GERD symptoms. The trial has specific eligibility criteria for participants, including currently being treated with a PPI but still experiencing GERD symptoms at least twice a week. There are also exclusion criteria, such as a history of serious arrhythmia or drug abuse, and women who are pregnant or not using contraception. The trial aims to determine the safety and efficacy of the drug for treating GERD symptoms.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on treating neuralgia and neuropathic peripheral pain using the drug sodium valproate. The diseases are identified by their ICD-10 codes, which are listed as ['G50.0', 'M54.81', 'B02.22', 'M79.2']. The eligibility criteria for the trial include having peripheral neuropathic pain and providing signed written informed consent. The exclusion criteria include having central neuropathic pain or a current or past hepatic disease.",
    "The sample is a record of a clinical trial for a drug called mp-214, which is being tested on patients diagnosed with schizophrenia. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for patients to participate in the trial. The inclusion criteria include obtaining written informed consent from the patient, a diagnosis of schizophrenia according to the DSM-IV-TR criteria, and normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG). The exclusion criteria include patients with a diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of unipolar depression using drugs such as escitalopram and pindolol. The eligibility criteria for the trial include patients aged between 18 and 65 years old, suffering from major depression according to DSM-IV with a MADRS score of at least 25, and not currently being treated with an antidepressant except for non-responders or those who cannot tolerate their current medication. The trial also requires informed consent from the patients. Exclusion criteria include any other Axis I disorder, non-responders to escitalopram in the past, pregnancy and breastfeeding, contraindications to the treatments, significant somatic comorbidity, high risk of suicidality, and women of childbearing age without a safe means of contraception. The diseases being studied are limited to unipolar depression, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on anaplastic thyroid cancer and includes a list of icd-10 codes for the disease. The trial involves the use of three drugs: ca4p, paclitaxel, and carboplatin. The eligibility criteria for the trial include confirmation of the disease through pathology review, refractory or progressed disease, limited systemic therapy, and adequate bone marrow and organ function. Exclusion criteria include tumors confined to the thyroid, brain metastasis, and history of certain medical conditions.",
    "The sample is a clinical trial for patients with transient ischemic attack or minor acute ischemic stroke. The trial is in phase 2/phase 3 and involves the use of aspirin, clopidogrel, and simvastatin. The eligibility criteria include being aged 40 years or older, having weakness or language disturbance at the time of the attack, and having a duration of neurological deficit of more than 5 minutes. Patients must not be candidates for acute thrombolysis or other acute intervention indicated as the current standard of care. Exclusion criteria include having pure sensory symptoms, being on certain medications, having a neurological deficit due to intracranial hemorrhage or tumor, and having a presumed cardiac source of embolus. Women who are pregnant or breastfeeding are also excluded. The trial requires written, informed consent from patients and has a follow-up period of at least 90 days.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on patients with metastatic breast cancer and involves the use of drugs such as trastuzumab and vinorelbine. The eligibility criteria for the trial include confirmation of carcinoma of the breast, metastatic breast cancer, HER-2/neu overexpression, age over 18, adequate hepatic, renal, and hematologic function, and adequate cardiac function. The trial also has exclusion criteria, such as no recent treatment with chemotherapy or trastuzumab, prior therapy with vinorelbine, and known hypersensitivity to certain proteins. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, which is a combination of phase 2 and phase 3. The trial is focused on colorectal cancer, with a list of associated ICD-10 codes. The trial involves two different drugs, cpt-11 and ts-1, as well as cpt-11, 5-fu, and l-lv. The eligibility criteria for the trial are also listed, including requirements such as age, performance status, and specific blood test results. Additionally, there are exclusion criteria listed, such as prior radiotherapy for colorectal cancer and other malignancies in the past 5 years.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying hypertension. The icd-10 codes associated with hypertension are listed, as well as the drugs being tested (olmesartan medoxomil and placebo). The eligibility criteria for participants are also listed, including requirements for blood pressure levels, negative test results for hepatitis B and C, and HIV, and exclusion criteria such as a history of congestive heart failure or sensitivity to olmesartan medoxomil.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the disease of ocular hypertension, which is identified by a list of ICD-10 codes. The drug being tested is bimatoprost. The eligibility criteria for the trial include a clinical diagnosis of glaucoma or ocular hypertension in both eyes and a requirement for IOP-lowering drug in both eyes. The exclusion criteria include uncontrolled medical conditions and ocular seasonal allergies within the past 2 years.",
    "The sample is a clinical trial for Parkinson's disease, in which patients with a modified Hoehn and Yahr scale of II to IV at \"on\" time are eligible. The trial is in phase 2/phase 3 and the patients must have received an individual dosage of L-DOPA at a stable dose for at least 4 weeks before the baseline visit. The trial aims to address therapeutically problematic issues or status based on L-DOPA therapy, such as wearing-off phenomena, no on/delayed on, dystonia at off time, on-off phenomena, freezing phenomena at off time, or sub-optimal dose of L-DOPA due to side effects or therapeutic strategy. The sample includes inclusion and exclusion criteria, such as excluding patients with atypical parkinsonian syndromes, dementia, psychiatric disorders, clinically significant ECG abnormalities, hypotension, or other clinically significant diseases. Patients who are pregnant or breastfeeding, sexually active females of childbearing potential not using a medically approved method of birth control, or those with certain serum levels or complications are also excluded.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the disease of seizures and includes a list of icd-10 codes associated with the disease. The trial involves two drugs, levetiracetam 1 g iv + lorazepam 2 mg iv and placebo + lorazepam 3 mg iv. The eligibility criteria for the trial includes having seizures as an inclusion criteria, while exclusion criteria includes pregnancy, renal failure, and hepatic impairment.",
    "The sample is a clinical trial for the treatment of restless legs syndrome. It is a phase 2/phase 3 trial that includes patients who are at least 18 years old and have been diagnosed with idiopathic RLS. The trial involves the use of the drugs rasagiline and placebo (sugar pill). The eligibility criteria include having moderate or severe symptoms of RLS, not currently receiving treatment for RLS, and being on a stable dose of certain antidepressants for at least 30 days prior to the baseline visit. Female subjects must not be of childbearing potential or must agree to use contraception for the duration of the study. The exclusion criteria include having signs consistent with a secondary cause of RLS, history of initial unresponsiveness to dopaminergic RLS treatment, and use of certain drugs or supplements contraindicated with rasagiline.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, rheumatoid arthritis), the corresponding ICD-10 codes, the drugs being tested (including sarilumab, placebo, methotrexate, and folic acid), and the eligibility criteria for participants. The eligibility criteria include specific requirements for the duration and severity of the disease, as well as exclusion criteria such as age restrictions and previous treatments. The sample also includes a disclaimer that the information provided is not exhaustive and may not include all relevant considerations for potential participants in the trial.",
    "The sample is a clinical trial for small cell lung cancer in phase 2/phase 3. The trial compares the effectiveness of carboplatin plus irinotecan versus carboplatin plus etoposide. The eligibility criteria for the trial include having cytological or histological proven SCLC Stage I or II at first diagnosis, no prior chemotherapy, measurable tumor disease, and a Karnofsky performance score of 70. The exclusion criteria include having a second malignancy (except basal cell carcinoma or CA in situ Cervix uteri), NYHA III, chronic diarrhea, or obstructive bowel syndrome.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (carcinoma, non-small-cell lung), the corresponding ICD-10 codes (D02.20, D02.21, D02.22), the drug being tested (1st line chemotherapy), and the eligibility criteria for participants. The inclusion criteria include having histologically confirmed non-small cell carcinoma of the lung, MUC1 antigen expression on the primary tumor or on metastasis, stage IIIb \"wet\" or IV disease, and adequate hematological, hepatic, and renal function, among others. The exclusion criteria include concomitant brain metastases, previous history of other malignancy, previous systemic therapy for advanced non-small cell cancer of the lung, and serious concomitant medical disorder, among others.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of obesity, with a list of associated ICD-10 codes. The trial involves the use of two drugs, cp-945,598 and sibutramine. The eligibility criteria for the trial include a BMI of 30-40 kg/m2 for subjects without additional co-morbidities, and a BMI of 27-40 kg/m2 for subjects with co-morbidities such as essential hypertension and/or dyslipidemia. The exclusion criteria include subjects with high blood pressure, type 2 diabetes, a history of eating disorders, and those taking appetite or weight modifying drugs.",
    "The sample is a record of a clinical trial for diabetic macular edema. The trial is in phase 2/phase 3 and the drug being tested is fluocinolone acetonide. The eligibility criteria for the trial include having DME in the study eye, edema involving fixation and being at least 1 disc area in size, visual acuity of \u226520 and \u226468 letters by ETDRS in the study eye, and having received at least one macular laser treatment > 12 weeks prior to entry into the study. The exclusion criteria include being pregnant or lactating, having an allergy to fluocinolone acetonide or any component of the delivery system, having any disease or condition that would preclude study treatment or follow up, and having a history of uncontrolled IOP within the last 12 months.",
    "The sample is a clinical trial for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. The trial is in phase 2/phase 3 and involves the use of two drugs, ethyl-eicosapentaenoic acid (EPA) and vitamins E + C. The trial also includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial include being admitted to a psychiatric hospital/department within the previous twenty-one days before screening, being less than fifteen years since first psychotic symptoms, being between the ages of 18-40, and speaking fluently a Scandinavian language. The exclusion criteria include having a diagnosis of substance dependence, known allergy to study medication, and currently taking warfarin or having anamnestic indicators of impaired haemostasis.",
    "The sample is a clinical trial for patients with end stage renal disease, in which they will receive mycophenolate sodium delayed release tablets or mycophenolate mofetil. The trial is a combination of phase 2 and phase 3. The eligibility criteria include being between 18-75 years old, having a negative standard crossmatch for T cells, and having a primary or secondary renal allograft from a living or deceased donor. Patients must also be willing to follow study procedures for 12 months and have signed an informed consent form. Exclusion criteria include having received an organ transplant other than a kidney, having a current malignancy or a history of malignancy within the past 5 years, and having uncontrolled infections or unstable medical conditions. Patients must also be able to take medications orally or via nasogastric tube by the morning of the second day following completion of the transplant procedure.",
    "The sample is a phase 3 clinical trial for patients with atrial fibrillation or atrial flutter. The trial involves the use of two drugs, dronedarone and placebo. The eligibility criteria include patients aged 75 years or older (or 70 years with certain risk factors), with hypertension, diabetes, prior stroke or embolism, left atrium diameter greater than or equal to 50 mm, or left ventricular ejection fraction less than 0.40. Patients must also have had an electrocardiogram showing they were or are in AF/AFL and another showing they were or are in sinus rhythm within the last 6 months. Exclusion criteria include refusal or inability to give informed consent, non-cardiovascular illnesses or disorders that could preclude participation, pregnancy or breastfeeding, previous participation in the trial, and certain cardiac conditions or concomitant medications.",
    "The sample is a phase 3 clinical trial for liver transplantation. The trial is testing the effectiveness of sirolimus (rapamune) and either cyclosporine or tacrolimus as immunosuppressive therapy for patients who have received a liver transplant and are currently taking calcineurin inhibitors, corticosteroids, and/or antimetabolites. The trial is open to patients aged 13 years or older (18 years or older in some regions) who have undergone liver transplantation within the past 6 to 144 months and have Cockcroft-Gault GFR values between 40 mL/min and 90 mL/min at screening. Patients with a history of nonhepatic transplantation, evidence of systemic infection, or known or suspected malignancy within the past 5 years are excluded from the trial.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients who are at least 50 years old and have a diagnosis of probable Alzheimer's disease with an MMSE score of 10-24. Patients must have a caregiver who can attend all study visits and have received continuous treatment with donepezil for at least 6 months prior to screening. The trial excludes patients with advanced, severe, progressive, or unstable diseases, a history of malignancy within the past 5 years, cerebrovascular disease within the past year, severe or unstable cardiovascular disease, and other conditions that may interfere with efficacy and safety assessments or put the patient at special risk. Other protocol-defined inclusion/exclusion criteria may also apply. The trial involves the use of rivastigmine transdermal patches.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of drugs for treating bipolar mania and bipolar disorder. The trial includes patients who meet the DSM-IV criteria for Bipolar I Disorder with manic or mixed symptoms. The trial excludes patients who are ultra rapid cyclers or have significant cardiovascular disease, including a history of QT prolongation and/or congenital long QT syndrome. The table also includes a list of icd-10 codes for the diseases being studied and a list of drugs being tested, including a placebo and ziprasidone oral capsule.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying congestive heart failure. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (dronedarone and placebo). The eligibility criteria for participants are also listed, including inclusion criteria such as being hospitalized with symptomatic CHF and having a left ventricular ejection fraction (LVEF) of \u226435%, and exclusion criteria such as having acute pulmonary edema or various heart conditions. The information provided is not intended to cover all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of acute myelogenous leukemia. The trial is testing the effectiveness of clofarabine (iv formulation) and cytarabine compared to a placebo. The eligibility criteria for the trial include being diagnosed with AML according to WHO classification, having relapsed after receiving up to 2 prior induction regimens or being refractory to not more than one prior combination chemotherapy induction regimen, being at least 55 years of age, having an ECOG score of 0-2, being able to comply with study procedures and follow-up examinations, having adequate liver and renal function, and being nonfertile or agreeing to use birth control during the study through the end of treatment visit and for at least 90 days after the last dose of study drug. Exclusion criteria include having received previous treatment with clofarabine, having received bolus, intermediate or high-dose cytarabine as induction therapy unless certain remission criteria are met, having received a hematopoietic stem cell transplant within the previous 3 months, having moderate or severe graft versus host disease, receiving any other chemotherapy or investigational therapy, having a psychiatric disorder that would interfere with consent, study participation, or follow-up, having an active, uncontrolled infection, having any other severe concurrent disease, or having a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system. Patients who have been diagnosed with another malignancy, unless disease-free for at least 5 years, are eligible for the study if definitive treatment for the condition has been completed. Patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are also eligible for the study. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed. Patients with clinical evidence suggestive of central nervous system involvement with leukemia are not eligible unless lumbar puncture confirms absence of leukemic blasts in the cerebrospinal fluid. Patients who are known to be HIV positive, pregnant, or lactating are also not eligible for the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of prostate cancer. The trial is focused on patients with metastatic prostate cancer that is unresponsive or refractory to hormone therapy. The trial requires patients to have detectable metastases and an ECOG performance status of \u22642 (or 3 if due to bone pain). Patients with any Gleason score are eligible, but they must have only received one prior treatment with systemic chemotherapy and have no prior treatment with gene therapy or immunotherapy for prostate cancer. Additionally, patients must be taxane na\u00efve and experiencing cancer-related pain. The trial will use chemotherapy (docetaxel and prednisone) as the treatment.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been diagnosed for at least 1 year before the screening visit and are insufficiently controlled with metformin alone or metformin with sulfonylurea at the time of the screening visit. The trial involves the drugs lixisenatide (ave0010), placebo, metformin, and sulfonylurea. The eligibility criteria for the trial include various inclusion and exclusion criteria such as HbA1c levels, age, pregnancy or breastfeeding, type 1 diabetes mellitus, unstable doses of metformin or sulfonylurea, FPG levels, history of hypoglycemia unawareness, body mass index, weight change, history of pancreatitis or inflammatory bowel disease, personal or family history of medullary thyroid cancer, history of metabolic acidosis, hemoglobinopathy or hemolytic anemia, history of myocardial infarction, stroke, or heart failure requiring hospitalization, history of drug or alcohol abuse, cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease, uncontrolled or inadequately controlled hypertension, laboratory findings, any clinically significant abnormality identified on physical examination, use of oral or injectable antidiabetic or hypoglycemic agents other than metformin and sulfonylurea, use of systemic glucocorticoids, use of any investigational drug, participation in a previous study with lixisenatide, renal impairment, clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, allergic reaction to any GLP-1 agonist in the past or to metacresol, and additional exclusion criteria at the end of the run-in phase.",
    "The sample is a phase 3 clinical trial for patients with ovarian cancer, peritoneal cancer, or cancer of the fallopian tube who have not responded to platinum and taxane treatment. The trial involves the use of tamoxifen and chemotherapy. The eligibility criteria include having a certain performance status, being at least 18 years old, and giving informed consent. Exclusion criteria include having symptomatic brain metastasis, certain blood counts, active infection or serious medical conditions, and previous treatment with tamoxifen. The sample also includes lists of disease names, ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients who have undergone a modified radical mastectomy and have histologically confirmed ER(-) PR(-) and HER-2(-) breast cancer. Patients must have positive axillary lymph nodes or negative axillary lymph nodes with age less than 35 years or grade III or intravascular cancer embolus. Patients must be between 18 and 65 years old, have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, and be able to give informed consent. Patients must not be pregnant and must have adequate bone marrow, renal, and hepatic function. Patients must not have received neo-adjuvant therapy, have cardiac dysfunction, uncontrolled medical problems, evidence of active acute or chronic infection, or hepatic, renal, or bone marrow dysfunction.",
    "The sample is a phase 3 clinical trial for patients with recurrent non-small cell lung carcinoma, stage IIIB or IV non-small cell lung cancer, or stage IIIA non-small cell lung cancer. The trial involves the drugs erlotinib hydrochloride and pemetrexed disodium. The eligibility criteria include having measurable disease, confirmed NSCLC, and having received only one prior chemotherapy regimen. Patients must also meet certain health requirements, such as having a certain level of blood counts and liver function. The trial excludes patients with certain medical conditions or prior treatments, and those with non-measurable disease.",
    "The sample is a phase 3 clinical trial for fibromyalgia and neurocognition. The trial involves the use of milnacipran and placebo drugs. The eligibility criteria include being between the ages of 18 and 65, having a specific diagnosis of fibromyalgia confirmed by a rheumatologist or physician, and meeting certain physical tender point examination criteria. Exclusion criteria include having bipolar or psychotic disorders, concomitant rheumatological disorders, substance dependence, and serious or unstable medical disorders. Participants must also be nonpregnant/nonlactating females or using adequate contraception if sexually active. Additionally, they must not have a history of hypersensitivity to milnacipran or certain CNS disorders that affect cognitive status. The trial also requires a minimum of 30 days on a stable dose of analgesics and a minimum of 4 weeks washout from certain medications and supplements. Narrow angle glaucoma is also an exclusion criterion.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who are currently experiencing an acute exacerbation of schizophrenia and excludes those with uncontrolled medical conditions or any other psychiatric disorder as a primary diagnosis. The trial involves the use of three drugs: asenapine, placebo, and olanzapine. The diseases are listed as 'schizophrenia' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial involves the use of the drugs cobi, drv, and nrtis. The eligibility criteria for the trial include being an adult over 18 years old, having no prior use of any approved or investigational antiretroviral drug, having plasma HIV-1 RNA levels of at least 1000 copies/mL at screening, and having normal electrocardiogram (ECG) and hepatic transaminases levels. The trial also requires adequate hematologic and renal function, and the use of protocol-recommended methods of contraception for females of childbearing potential. Exclusion criteria include previous or current use of darunavir, a new AIDS-defining condition diagnosed within the 30 days prior to screening, and ongoing active liver disease or experiencing decompensated cirrhosis irrespective of liver enzyme levels.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder in pediatric patients. The trial involves the use of the drug asenapine and a placebo, as well as a rescue medication. The eligibility criteria include having a confirmed diagnosis of bipolar I disorder, being between the ages of 10 and 17, and having a caregiver who agrees to ensure compliance with the study procedures. Exclusion criteria include a history of bipolar II disorder or other psychotic disorders, substance abuse within the past 6 months, and a risk of self-harm or harm to others. Participants must also not be pregnant or lactating, and must not have a history of seizure disorder or tardive dyskinesia or dystonia.",
    "The sample is a phase 3 clinical trial for asthma. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. The inclusion criteria require patients to be at least 12 years old, have a history of asthma for at least 12 months, and have used an inhaled corticosteroid for at least 4 weeks prior to the screening visit. Patients must also demonstrate an FEV1 of 40% to 80% of predicted normal values and documented reversibility within 12 months of the screening visit. The exclusion criteria include life-threatening asthma within the past year, history of systemic corticosteroid medication within 3 months before the screening visit, and significant non-reversible pulmonary disease. The sample also includes a list of drugs being tested, including flutiform 250/10, skp-fluticasone, and flovent fluticasone hfa.",
    "The sample is a phase 3 clinical trial for patients with uncontrolled hypertension. The trial is testing the effectiveness of the drug telmisartan/amlodipine. The eligibility criteria include being 18 years or older, having uncontrolled hypertension despite at least 6 weeks of stable treatment with antihypertensive medication, and meeting certain creatinine levels. Exclusion criteria include pregnancy or nursing, secondary hypertension, renal dysfunction, and various other medical conditions. The trial aims to determine if telmisartan/amlodipine is a safe and effective treatment for uncontrolled hypertension.",
    "The sample is a phase 3 clinical trial for the treatment of gastroesophageal reflux disease. The trial involves the use of the drug pantoprazole sodium enteric-coated spheroid. The eligibility criteria for the trial include the ability to undergo endoscopy with required biopsy, ages 1 through 5 years, and endoscopically confirmed GERD by positive endoscopic evidence of reflux related esophagitis or positive histologic evidence of esophagitis consistent with GERD. Exclusion criteria include a history or presence of upper gastrointestinal anatomic or motor disorders, known current or active cow's milk allergy, malignancy, and other exclusions apply. The diseases associated with the trial are listed as 'gastroesophageal reflux' and the corresponding ICD-10 codes are [\"['K21.9', 'K21.00', 'K21.01']\"].",
    "The sample is a phase 3 clinical trial for bladder cancer. The trial involves the drugs apaziquone and placebo. The eligibility criteria for the trial include having written informed consent, being at least 18 years old, having transitional cell carcinoma of the bladder with clinically apparent tumor Ta, grade G1-G2, and being willing and able to abide by the protocol. The exclusion criteria include having more than 5 bladder tumors, having a single bladder tumor exceeding 3.5 cm in diameter, having a single, primary bladder tumor <0.5 cm and no previous diagnosis of bladder cancer, having received EOquin(r), having any bladder tumor known to be other than tumor Ta or grade G1 or G2, having any bladder tumor with histology other than transitional cell carcinoma, having carcinoma in situ (CIS), having an active urinary tract infection, having a bleeding disorder or a screening platelet count < 100 x 109/L, having any unstable medical condition that would make it unsafe for him/her to undergo TURBT under general or spinal anesthesia, having screening hemoglobin < 10 mg/dL, a screening absolute neutrophil count < 1.5 x 109/L, having a known immunodeficiency disorder, having received any investigational treatment within the past 30 days, being breast feeding, having a history of interstitial cystitis, having a history of allergy to red color food dye, or having had transitional cell carcinoma of the bladder within the past 4 months.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia or psychotic disorders. The trial involves the use of drugs such as aripiprazole, risperidone long acting injectable (lai), and quetiapine. The eligibility criteria for the trial include a diagnosis of schizophrenia or schizoaffective disorder, current treatment with specific medications at specific doses, and stability on medication for at least 4 weeks. Exclusion criteria include a diagnosis other than schizophrenia or schizoaffective disorder, treatment with certain antipsychotic agents, known hypersensitivity to certain drugs, and use of mood stabilizers or antidepressants that are not on a stable dose for at least 3 months. Pregnant or nursing females or those lacking adequate contraception are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of embolism and thrombosis. The trial involves the use of drugs such as idrabiotaparinux sodium, warfarin, and enoxaparin, as well as placebos. The eligibility criteria for the trial include having symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis, and not having certain medical conditions or allergies. The trial excludes individuals with end stage renal failure, hepatic failure, uncontrolled hypertension, active bleeding or high risk for bleeding, pregnancy or childbearing potential without proper contraceptive measures, threatened abortion, breastfeeding, known allergy to certain drugs or proteins, hypersensitivity to certain drugs or pork products, indication of prolonged anticoagulation therapy for other reasons than PE, and life expectancy less than 6 months.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients who have been diagnosed with bipolar I disorder and are currently experiencing a manic or mixed episode or are between mood episodes. The trial involves the use of olanzapine, risperidone long acting injectable (lai), and a placebo. The eligibility criteria include having had at least 2 bipolar mood episodes within the last year, excluding the current episode, and meeting certain YMRS and CGI-S scores. Patients who are currently receiving an antipsychotic other than risperidone or a mood stabilizer must have received this other medication at the same dosage for a minimum of 4 weeks and must be either experiencing problems of safety or tolerability with the antipsychotic or mood stabilizer or request a change of medication. The exclusion criteria include having a history of more than 4 mood episodes each year, having ADHD, anxiety disorder, or panic disorder as the primary diagnosis, and having certain comorbid or active Axis I disorders. Patients with certain chronic or serious general medical illnesses are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of breast cancer. The trial is looking at the effectiveness of two drugs, trastuzumab emtansine and \"treatment of physician's choice\", in patients with HER2-positive metastatic or unresectable locally advanced/recurrent breast cancer. The trial has specific eligibility criteria, including age, disease progression, prior treatment with certain drugs, and adequate organ function. Patients with brain metastases that are untreated or symptomatic are excluded from the trial. The trial is designed to evaluate the safety and efficacy of the drugs in treating breast cancer.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for patients with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and eligibility criteria for patients to participate in the trial. The inclusion criteria include having a prior diagnosis of type 2 diabetes mellitus, being on a diet and exercise regimen for 12 weeks prior to informed consent, and having a glycosylated haemoglobin (HbA1c) level within a certain range. The exclusion criteria include uncontrolled hyperglycaemia, impaired renal function, recent acute coronary syndrome, stroke or transient ischemic attack (TIA), and indication of liver disease.",
    "The sample is a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis. The trial involves the use of the drugs ambrisentan and placebo. The eligibility criteria for participants include being between 40 and 80 years old, having a diagnosis of IPF, having less than or equal to 5% fibrosis in the lung, being able to perform certain physical tests, having normal liver function, and being willing to use contraception. Exclusion criteria include having other lung diseases, recent hospitalization for an IPF exacerbation, and chronic use of certain medications.",
    "The sample is a phase 3 clinical trial for chronic lymphocytic leukemia. The trial includes patients who are 18 years or older and have been diagnosed with B-cell CLL by NCI Working Group criteria. Patients who have had no more than one previous line of chemotherapy and are expected to survive for more than 6 months are eligible to participate. The trial involves the use of rituximab, fludarabine phosphate, and cyclophosphamide. The eligibility criteria include acceptable hematologic, liver, renal, and pulmonary function, negative serum pregnancy test, and written informed consent. Exclusion criteria include prior treatment with interferon, rituximab, or other monoclonal antibody, prior bone marrow transplant, and severe non-hematological toxicity or prolonged cytopenia on prior fludarabine or nucleoside analogue regimen. Other exclusion criteria include medical conditions requiring long-term use of systemic corticosteroids, active bacterial, viral, or fungal infection requiring systemic therapy, severe cardiac disease, seizure disorders requiring anticonvulsant therapy, severe chronic obstructive pulmonary disease with hypoxemia, uncontrolled diabetes mellitus or hypertension, transformation to aggressive B-cell malignancy, known infection with HIV, HCV, or hepatitis B, treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study, known hypersensitivity or anaphylactic reactions to murine antibodies or proteins, and any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.",
    "The sample is a phase 3 clinical trial for the treatment of obesity in men and women with type 2 diabetes. The trial includes the use of lorcaserin, a drug that is administered either once daily or twice a day, as well as a matching placebo. The trial has specific eligibility criteria, including a BMI range of 27 to 45 kg/m2 and the ability to complete a 1-year study. Exclusion criteria include pregnancy, recent use of certain medications, and certain medical conditions. The trial is designed to evaluate the effectiveness of the treatment over the course of a year.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes who are not well controlled on one, two, or three oral antidiabetic medications. The trial is testing the effectiveness of a combination of drugs including ly2189265, exenatide, metformin, pioglitazone, and a placebo. The eligibility criteria include having a HbA1c level between 7 and 11 if taking one oral antidiabetic medication, or between 7 and 10 if taking two or three oral antidiabetic medications, being able to tolerate a minimum dose of 1500mg metformin and 30mg pioglitazone per day, and being willing to inject subcutaneous medication up to two times per day. The exclusion criteria include having type 1 diabetes, a HbA1c level equal to or less than 6.5, chronic insulin use, taking drugs to promote weight loss, and having a history of certain medical conditions such as heart failure or renal disease.",
    "The sample is a phase 3 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as golimumab and methotrexate, as well as placebo injections and capsules. The eligibility criteria for participants include having a diagnosis of rheumatoid arthritis for at least 3 months, having active RA with at least 4 swollen and 4 tender joints, and meeting certain laboratory criteria. Participants must also have been treated with and tolerated methotrexate at a certain dose for at least 3 months prior to screening. There are also exclusion criteria, such as having had prior treatment with certain drugs or having a history of certain infections.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer using the drug leuprolide acetate. The trial is open to males over the age of 18 with histologically proven prostate cancer who may benefit from medical androgen deprivation therapy and have a life expectancy of at least 1 year. The trial has a list of inclusion and exclusion criteria, including adequate renal and hepatic function, ability to comprehend the study and comply with its requirements, and signed written informed consent. Exclusion criteria include evidence of brain metastases or spinal cord compression, severe urinary tract obstruction, excruciating pain from osseous deposits, and previous cancer systemic therapy or hormonal therapy for prostate cancer. The trial also excludes patients with serious concomitant illnesses or diseases that may interfere with their ability to receive treatment.",
    "The sample is a clinical trial for Huntington's disease, in which the phase is a combination of phase 2 and phase 3. The trial involves testing the effectiveness of three different doses of a drug called ACR16 (10mg, 22.5mg, and 45mg) on patients with Huntington's disease. The eligibility criteria for the trial include having clinical features of Huntington's disease, a positive family history and/or the presence of \u2265 36 CAG repeats in the Huntington gene, being male or female age \u2265 30 years, being able to take oral medication and comply with study procedures, being ambulatory and able to travel to the assessment center, having a caregiver or family member to accompany the subject to two visits, and having a sum of \u2265 10 points on the mMS at the screening visit. The exclusion criteria include treatment with certain medications, use of investigational products, certain medical conditions, and previous participation in a clinical study with ACR16.",
    "The sample is from a phase 3 clinical trial for postmenopausal osteoporosis. The trial includes ambulatory postmenopausal women who have at least one moderate or two mild atraumatic vertebral fractures and a minimum of seven evaluable nonfractured vertebrae. The patients must have hip or lumbar spine BMD measurement at least 1.0 standard deviation below the average bone mass for young, healthy women (T-score). The trial includes teriparatide, calcium supplement, vitamin D supplement, and placebo as drugs. The eligibility criteria include normal or clinically nonsignificant abnormal laboratory values, and exclusion criteria include fractures in areas of bone affected by diseases other than osteoporosis, current or recent metabolic bone disorders other than postmenopausal osteoporosis, and poor medical or psychiatric risk for treatment with an investigational drug.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two types of esophagitis - reflux and peptic. The diseases are identified by their corresponding ICD-10 codes. The trial involves three drugs - dexlansoprazole mr, dexlansoprazole mr, and lansoprazole. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Inclusion criteria require that the subject has endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D). Exclusion criteria include a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori, use of certain prescription or non-prescription drugs, and a history of certain medical conditions or surgeries.",
    "The sample is a phase 3 clinical trial for the treatment of chronic low back pain. The trial includes patients who have been experiencing moderate to severe chronic low back pain for at least 3 months and have not found relief with non-opioid medication. The trial involves the use of buprenorphine transdermal system and a placebo. Patients who have had back surgery within the past 6 months or who are allergic to buprenorphine or other opioids are excluded from the trial. Other protocol-specific inclusion/exclusion criteria may also apply.",
    "This sample is for a phase 3 clinical trial for the treatment of hyperlipidemia. The trial involves the use of drugs such as fenofibrate/simvastatin and pravastatin. The eligibility criteria for the trial include having mixed dyslipidemia, while exclusion criteria include known hypersensitivity to the drugs, pregnancy or lactation, contra-indication to the drugs, and unstable or severe cardiac disease.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of psoriatic arthritis using the drug adalimumab. The eligibility criteria for the trial include having at least 3 tender or painful joints and 3 swollen joints despite standard psoriatic arthritis therapy, as well as having an unsatisfactory response or intolerance to at least two prior or ongoing DMARDs (one of which has to be methotrexate). The exclusion criteria include a history of cancer or other inflammatory joint diseases, unstable diseases, and a history of active tuberculosis or other infections. The sample also includes the disease name, icd-10 codes, and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have provided informed consent and meet the DSM-IV-TR criteria for schizophrenia. The trial also requires patients to have a diagnosis of schizophrenia for at least one year before the start of the trial. The trial involves the use of the drugs cariprazine and placebo. The eligibility criteria include a normal physical examination, laboratory tests, vital signs, and electrocardiogram. Exclusion criteria include patients with other psychotic disorders, bipolar disorder, or substance abuse within the prior 3 months. Patients with certain personality disorders or cognitive disorders are also excluded. Pregnant or breastfeeding patients are not eligible for the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of fibromyalgia. The trial includes only patients who have been diagnosed with fibromyalgia according to the 1990 American College of Rheumatology criteria. The drug being tested is milnacipran hydrochloride. The eligibility criteria for the trial include several exclusion criteria such as psychiatric illness, depression, suicidal risk, substance abuse, pulmonary dysfunction, renal impairment, active cardiac disease, liver disease, autoimmune disease, cancer, sleep apnea, and inflammatory bowel disease.",
    "The sample is a phase 3 clinical trial for patients with osteoarthritis, hip or knee pain, and lower back pain. The trial is testing the effectiveness of two drugs, oxycodone cr and tapentadol (cg5503) er, for pain relief. The eligibility criteria include having a clinical diagnosis of osteoarthritis or low back pain for at least 3 months, being dissatisfied with current analgesic therapy, and having a pain intensity greater than 4 on a Numerical Rating Scale. Exclusion criteria include a history of seizure disorder or epilepsy, recent traumatic brain injury or stroke, history of malignancy within the past 2 years, and significant pain associated with conditions other than osteoarthritis or low back pain.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on chronic obstructive pulmonary disease (COPD) and involves the use of three different drugs: formoterol turbuhaler\u00ae 4.5mg, formoterol turbuhaler\u00ae 9 mg, and turbuhaler\u00ae placebo. The trial has a list of inclusion and exclusion criteria, including age, smoking history, lung function parameters, and the absence of certain medical conditions. The sample also includes a list of ICD-10 codes associated with COPD.",
    "The sample is a phase 3 clinical trial for postmenopausal women between the ages of 48 and 68 who are physically and mentally healthy and have an intact uterus. The trial is focused on treating sexual dysfunction and includes a list of diseases and corresponding icd-10 codes. The drugs being tested are tibolone and estradiol-norethisterone. The eligibility criteria include having a decreased satisfactory sexual activity compared to younger age and not having sexual problems caused by relationship/partner problems. The trial also requires an established sexual relationship of at least 6 months duration prior to screening and normal mammography within 6 months prior to randomization. The exclusion criteria include various medical conditions and medications that could interfere with the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of non-small-cell lung carcinoma. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are also included, with specific inclusion and exclusion criteria listed. The inclusion criteria include advanced non-small-cell lung cancer with pleural effusion or stage IV, no prior systemic treatment for non-small-cell lung cancer, and an Eastern Cooperative Oncology Performance Status (ECOG PS) of 0 or 1. The exclusion criteria include small cell or carcinoid lung cancer, known central nervous system metastasis, and pre-existing auto-immune or antibody mediated diseases.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of restless legs syndrome. The trial includes patients with primary RLS, based on the International RLS Study Diagnostic Criteria. The trial involves the use of xp13512 600mg, xp13512 1200mg, and placebo drugs. The eligibility criteria for the trial include exclusion of patients with sleep disorders, neurologic diseases or movement disorders, abnormal laboratory results, electrocardiogram (ECG) or physical findings, pregnant or lactating women, and women of childbearing potential who are not practicing an acceptable method of birth control.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on macular edema associated with diabetes mellitus. The icd-10 codes associated with the disease are listed. The trial involves the use of two drugs, standard of care and macugen. The eligibility criteria for the trial are also listed, including inclusion criteria such as having macular edema associated with diabetes and a visual acuity between 20/50 and 20/200, and exclusion criteria such as recent laser therapy in the eye, recent signs of uncontrolled diabetes, blood pressure worse than 160/100, and severe cardiac disease.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed as [\"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", \"I10\"]. The drug being tested is nifedipine (also known as adalat or baya1040). The eligibility criteria for the trial are listed under inclusion and exclusion criteria, with the inclusion criteria being patients who completed the 8 week double blind treatment phase of Study 13176 and for whom the test drug is tolerable, and the exclusion criteria being patients with expected difficulties for the continuous 1 year follow up.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes related to the disease. The trial involves the drug triptorelin (decapeptyl\u00ae) and has specific eligibility criteria for patients to participate. Inclusion criteria include being 18 years or older, having a confirmed diagnosis of locally advanced or metastatic prostate cancer, and having an estimated survival time of greater than 8 months. Exclusion criteria include previous surgical castration, recent prostate cancer therapy, and low testosterone levels. The sample also includes detailed information on the trial's eligibility criteria.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease thromboembolism and includes a list of associated ICD-10 codes. The trial involves the use of two drugs, certoparin and unfractionated heparin. The eligibility criteria for the trial includes hospitalization of medical patients who are 70 years or older, have an acute medical illness with a significant decrease in mobility expected for at least 4 days, and have provided written informed consent. The exclusion criteria includes factors such as prior major surgery or trauma, immobilization longer than 3 days prior to randomization, and indication for anticoagulatory or thrombolytic therapy. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with relapsing-remitting multiple sclerosis. The trial includes a list of icd-10 codes for the disease, a list of drugs being tested (fingolimod 1.25 mg, fingolimod 0.5 mg, and placebo), and eligibility criteria for patients to participate in the trial. Inclusion criteria include being between the ages of 18-55, having a relapsing-remitting disease course, and having an EDSS score of 0-5.5. Exclusion criteria include having other chronic diseases of the immune system, malignancies, acute pulmonary disease, cardiac failure, and being pregnant or nursing. The trial also has other protocol-defined inclusion/exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease pharyngitis and includes a list of associated ICD-10 codes. The trial involves the use of the drugs celecoxib and placebo. The eligibility criteria for the trial include a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis, and a willingness to abstain from food and drink (except for trial medication) for two hours before and after drug administration. Exclusion criteria include recent use of analgesic/antipyretic medication and regular use of inhaled therapy.",
    "The sample is from a phase 3 clinical trial for the treatment of chronic low back pain. The trial is testing the effectiveness of oxycodone/naloxone controlled-release compared to a placebo. The eligibility criteria for the trial include being at least 18 years old, having moderate to severe chronic low back pain for at least 3 months, and being on a stable opioid regimen for at least 4 weeks prior to the screening visit. The trial also requires subjects to have an average pain score of at least 5 on a numerical rating scale and to be willing and able to comply with the protocol. Exclusion criteria include pregnancy, hypersensitivity to opioids, and a history of opioid or drug abuse.",
    "The sample is a record of a clinical trial for the treatment of plaque-type psoriasis in phase 3. The trial involves the use of two drugs, secukinumab 150mg and secukinumab 10mg/kg i.v. regimen. The eligibility criteria for the trial include having achieved a partial response after twelve weeks of treatment with no major protocol deviations in a previous study, being able to communicate with the investigator, and not being pregnant or lactating. The exclusion criteria include having forms of psoriasis other than chronic plaque-type, ongoing use of prohibited psoriasis treatments, and previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor, except secukinumab in study CAIN457A2304.",
    "The sample is a phase 3 clinical trial for patients with psoriatic arthritis. The trial is testing the effectiveness of infliximab and methotrexate, either alone or in combination, as a treatment for the disease. The eligibility criteria for the trial include having a diagnosis of psoriatic arthritis with peripheral polyarticular involvement, being at least 18 years old, having active disease at the time of screening, and meeting certain laboratory test criteria. Patients must also confirm that they are practicing adequate contraception and must not have any exclusion criteria, such as being pregnant or having a history of drug abuse. The trial excludes patients with other inflammatory diseases that might interfere with the evaluation of psoriatic arthritis, as well as those who have previously received infliximab or methotrexate.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of asthma. The icd-10 codes associated with the disease are listed. The drug being studied is budesonide/formoterol. The eligibility criteria for the trial are also listed, including age range and presenting symptoms, as well as exclusion criteria such as hospital admission and certain levels of inhaled corticosteroids.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes the use of drugs such as ciclesonide, placebo, and salbutamol. The eligibility criteria for the trial includes having a history of asthma for at least 6 months, being able to demonstrate optimal use of MDI (inhalation technique), and having lung function and reversibility within specified limits. The exclusion criteria includes having concomitant severe diseases, diseases that are contraindications for the use of inhaled steroids, having two or more inpatient hospitalizations for asthma within the last year, having a respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study, using systemic steroids within the last 30 days prior to inclusion, beginning or changing immunotherapy within the last 6 months prior to inclusion, and being unable to follow the procedures of the study.",
    "The sample is a phase 3 clinical trial for restless legs syndrome. The trial includes patients with primary RLS based on the International RLS Study Group Diagnostic Criteria. The trial excludes patients with sleep disorders that may affect the assessment of RLS, neurologic diseases or movement disorders, abnormal laboratory results, ECG or physical findings, pregnant or lactating women, and women of childbearing potential who are not practicing an acceptable method of birth control. The trial involves the use of two different formulations of the drug gen (xp13512) and a placebo. The icd-10 code for restless legs syndrome is G25.81.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial includes patients between the ages of 6 and 15 who have a positive test response to house dust and/or dust mites on serum antigen-specific IgE antibody test and have a clinical history of perennial allergic rhinitis for at least one year. The trial involves the use of the drug fluticasone furoate and a placebo. The eligibility criteria include informed consent, specific age range, ALT levels, and completion of a patient diary. Exclusion criteria include recent participation in a study, use of certain medications, and a history of alcohol or drug abuse. The trial aims to assess the efficacy of the drug in reducing the total nasal symptom score (TNSS) in patients with perennial allergic rhinitis.",
    "The sample is a phase 3 clinical trial for asthma patients between the ages of 12 and 17. The trial requires patients to have a history of asthma for at least 3 months and to have been on maintenance treatment with an inhaled corticosteroid for at least 4 weeks prior to enrollment. Patients must also be symptomatic and have a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 60% and 90% of predicted normal. The trial involves the use of tiotropium high dose, tiotropium low dose, and a placebo. Patients must be able to use the Respimat\u00ae inhaler correctly and perform all trial-related procedures. The trial has a list of exclusion criteria, including significant disease other than asthma, abnormal haematology or blood chemistry, and history of heart disease. Female patients of child-bearing potential must be using a highly effective method of birth control. The trial also has a list of medications that patients cannot have taken within a certain timeframe prior to enrollment.",
    "The sample is a phase 3 clinical trial that involves patients with cardiovascular diseases and diabetes mellitus. The trial is testing two drugs, mk0653a and ezetimibe (+) simvastatin, and a comparator drug, atorvastatin, for a duration of 6 weeks. The eligibility criteria for the trial include being over 18 years old, having been treated with a daily dose of atorvastatin 40 mg for at least 3 months, and having existing coronary heart disease and cholesterol levels above 4.0 mmol/l. The exclusion criteria include uncontrolled diabetes, elevated liver function tests, elevated creatine kinase, triglycerides above 4.5 mmol/l, drug or alcohol dependency within 6 months prior to visit 1, women receiving hormonal therapy who have not been maintained on a stable dose and regimen for at least 8 weeks and are willing to continue the same regimen for the duration of the study, women of childbearing potential not using an acceptable method of birth control, and women who are pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. The trial involves testing the effectiveness of several drugs, including arformoterol tartrate inhalation solution, arformoterol 25 \u0173g bid, formoterol 12 \u0173g bid, and a placebo. The eligibility criteria for the trial include being at least 35 years old, having a pre-established diagnosis of non-asthmatic COPD, having a smoking history of at least 15 pack-years, and having a baseline breathlessness severity grade of at least 2 on the Modified Medical Research Council (MMRC) Dyspnea Scale Score. Female subjects must have a negative pregnancy test and be using an acceptable method of birth control if they are of childbearing potential. Subjects must also be in general good health. Exclusion criteria include a history of asthma (except for childhood asthma), a blood eosinophil count greater than 5% of total white blood cell count, a febrile illness within 72 hours before the screening visit, and a chest x-ray suggesting a diagnosis other than COPD.",
    "The sample is a phase 3 clinical trial for renal transplantation. The trial involves the use of three drugs: cyclosporin a, belatacept less intensive regimen (li), and belatacept more intensive regimen (mi). The eligibility criteria for the trial include being a first-time recipient of a kidney transplant from a deceased donor, meeting specific donor criteria, and not having certain exclusion criteria such as a positive T-cell lymphocytotoxic crossmatch or a history of cancer in the last 5 years. The trial also has a long-term extension study for subjects who have completed three years of study treatment.",
    "The sample is a phase 3 clinical trial for individuals who are at least 18 years old and have documented evidence of HIV-1 infection and painful HIV-associated distal symmetrical polyneuropathy. The trial is testing the effectiveness of a capsaicin dermal patch as a treatment for the pain associated with this condition. The trial has a list of inclusion and exclusion criteria, including a Karnofsky Performance Score of greater than or equal to 60 and intact, unbroken skin over the painful area(s) to be treated. The trial also has a list of diseases and icd-10 codes, as well as a list of drugs.",
    "The sample is a phase 3 clinical trial for sickle cell disease and sickle cell anemia. The trial is testing a drug called ica-17043. The eligibility criteria for the trial include having successfully completed a previous study, being on a stable dose of HU for at least 3 months prior to Day 1, and giving written informed consent. Exclusion criteria include being pregnant or unsuitable for participation in a long-term study. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of phenylketonuria. The trial involves the use of sapropterin dihydrochloride and a placebo. The eligibility criteria include being at least 8 years old, having a confirmed diagnosis of PKU, and being willing to continue the current diet unchanged during the study. Participants must also be willing to provide written informed consent and comply with all study procedures. Exclusion criteria include hypersensitivity to sapropterin dihydrochloride, breastfeeding or planning to become pregnant during the study, and any condition that would interfere with study participation or safety.",
    "The sample is a phase 3 clinical trial for patients with intermediate- or high-grade non-Hodgkin's lymphoma. The trial includes patients with bulky stage II, III, or IV disease who are classified as high-intermediate or high-risk according to the International Age Adjusted Index. The trial involves the use of the CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, and vincristine sulfate drugs. The eligibility criteria include various disease and patient characteristics, such as age, performance status, and renal function. Patients must not have prior lymphoma, Hodgkin's lymphoma, myelodysplastic syndromes, or leukemia. The trial also includes restrictions on prior concurrent therapy, such as no prior radiotherapy for lymphoma and no prior chemotherapy for lymphoma except for a single course of CHOP/CHOP-R.",
    "The sample is a phase 3 clinical trial that involves patients with various diseases such as colorectal cancer, depression, esophageal cancer, and lung cancer. The trial aims to test the effectiveness of escitalopram oxalate compared to a placebo. The eligibility criteria for patients include having a diagnosis of certain stages of cancer, meeting specific criteria for major depressive disorder, and not having certain medical conditions or substance abuse disorders. Patients must also not be pregnant and cannot be taking other antidepressant medications or psychostimulants during the trial.",
    "The sample is a phase 3 clinical trial for insomnia and bipolar disorder. The trial includes patients between the ages of 18 and 65 who have been diagnosed with bipolar I disorder and are experiencing mild to moderate manic symptoms. They must also be experiencing a clinically significant sleep disturbance and be receiving at least one mood stabilizing medication. The trial involves the use of the drug ramelteon and a placebo. Patients must meet certain inclusion criteria, such as signing an informed consent document and practicing medically acceptable contraception if female. Exclusion criteria include experiencing suicidal or homicidal ideation, having a current diagnosis of delirium or dementia, and having serious general medical illnesses.",
    "The sample is a clinical trial for impetigo, a skin infection. The trial is in phase 2/phase 3 and involves testing experimental and placebo topical gels containing cd07223. The eligibility criteria for participants include having a clinical diagnosis of primary impetigo, having at least one and no more than ten lesions, and having a Skin Infection Rating Scale (SIRS) total score of the Target Lesion of at least 4. Exclusion criteria include having other active skin diseases, requiring oral antibiotic treatment, having signs and symptoms of another current infection requiring antibiotic treatment, and having a history of Hepatitis B or C, HIV/AIDS, or other immunodeficiency disease. Participants must not have used systemic antibiotics or systemic steroids within 14 days prior to study entry, and must not have used topical antibiotics, topical antibacterials, topical antifungals or topical steroids within 14 days prior to study entry on any skin lesion. They must not have participated in any other clinical study or used any investigational drugs or investigational device within 30 days prior to enrollment.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and depression in patients aged 60 years or older. The trial is testing the effectiveness of two formulations of the drug lamotrigine. The eligibility criteria include a diagnosis of bipolar disorder, a HAM-D score of over 18, and no contraindications to lamotrigine. Exclusion criteria include chronic psychotic conditions, substance dependence, dementia, recent cardiovascular events, and high risk for suicide. The trial requires participants to be able to communicate in English and does not require an informant, although it is encouraged.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of sitagliptin 100 mg q.d./pioglitazone 30 mg q.d and a placebo comparator. The eligibility criteria include being 18 years or older and having type 2 diabetes mellitus, while the exclusion criteria include having a history of type 1 diabetes mellitus or ketoacidosis, being on antihyperglycemic agent therapy within the prior 4 months, or being on more than 4 weeks of antihyperglycemic therapy over the prior 2 years. The diseases are listed as 'type 2 diabetes mellitus', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), a list of diseases (in this case, only one disease is listed - benign prostatic hypertrophy), a list of ICD-10 codes associated with the disease, a list of drugs being tested (ozarelix/placebo and placebo), and eligibility criteria for participants. The eligibility criteria include questions related to age, symptoms, urinary flow rate, and willingness to avoid other BPH treatments during the study. Exclusion criteria include a history of prostate cancer or high PSA levels, prior surgeries or radiation, and certain medication use.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes that is not well controlled on one, two, or three oral antidiabetic medications. The trial involves the use of insulin glargine, ly2189265, metformin, and glimepiride. The eligibility criteria include having a glycosylated hemoglobin (HbA1c) level between 7 and 11 if taking one oral antidiabetic medication, or between 7 and 10 if taking two or three oral antidiabetic medications. Patients must also be willing to inject subcutaneous medication once weekly for LY2189265 or once daily for Insulin Glargine, have a stable weight for 3 months prior to screening, and have a body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m^2). Females of childbearing potential must test negative for pregnancy at screening and be willing to use a reliable method of birth control during the study and for 1 month following the last dose of study drug. Exclusion criteria include having type 1 diabetes, chronic insulin use, taking drugs to promote weight loss, and having a history of heart failure, gastrointestinal problems, liver disease, or renal disease.",
    "The sample is a phase 3 clinical trial for chronic inflammatory demyelinating polyradiculoneuropathy. The trial is testing the effectiveness of immune globulin iv (human), 10% caprylate/chromatography purified and albumin (human) 25%, united states pharmacopeia (usp) as treatments for the disease. The eligibility criteria for the trial include having a documented diagnosis of CIDP made by a neurologist, fulfilling INCAT neurophysiological criteria for focal demyelinating polyradiculoneuropathy, and having an overall INCAT score between 2-9 with significant disability in upper or lower limb function in at least 2 limbs. The exclusion criteria include recent treatment with IGIV or plasma, recent use of steroids or immunomodulatory/immunosuppressive agents, and various other conditions that could affect protein catabolism and/or immunoglobulin G (IgG) utilization. Females who are pregnant, breastfeeding, or of childbearing potential and unwilling to practice adequate contraception throughout the study are also excluded.",
    "The sample is a phase 3 clinical trial for patients with clear cell renal cell carcinoma. The trial includes patients with locally advanced or metastatic RCC who have received only one prior systemic treatment with cytokine-based therapy or no prior systemic therapy. The trial involves the use of pazopanib and placebo drugs. The eligibility criteria include having measurable disease, adequate organ function, and meeting specific medical and demographic requirements. The exclusion criteria include having certain medical conditions, taking prohibited medications, or having received prior treatment with drugs that target VEGF or VEGF receptors.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases: indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The trial includes a list of ICD-10 codes for the diseases, a list of drugs being tested, and eligibility criteria for patients to participate in the trial. The eligibility criteria include specific requirements for the patient's medical history, disease stage, and overall health. The sample also includes exclusion criteria, which outline conditions that would disqualify a patient from participating in the trial.",
    "The sample is a record of a clinical trial in phase 3, focused on chronic pain. The trial involves the use of two drugs, oros hydromorphone and placebo, and includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial are listed, including requirements for a primary clinic diagnosis of osteoarthritis pain of the hip or knee for at least 6 months and daily opioid medication. The exclusion criteria are also listed, including joint replacement of the hip or knee, history of drug or alcohol abuse, fibromyalgia, major depression or anxiety, and pregnancy or breastfeeding in women.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drugs duloxetine and placebo in treating depression and cognition. The trial has eligibility criteria for participants, including having a diagnosis of major depression and being able to visit the doctor's office for tests and procedures. There are also exclusion criteria, such as having a current or previous major psychiatric disorder other than depression and having taken a drug within the last 30 days that has not been approved for use by governmental authorities. The diseases being studied are depression and cognition, and their corresponding ICD-10 codes are listed.",
    "The sample is a phase 3 clinical trial for the treatment of non-muscle invasive bladder cancer. The trial involves the use of two drugs, epirubicin hydrochloride and mitomycin c. The eligibility criteria for the trial include a diagnosis of non-muscle invasive bladder cancer, recurrent disease after undergoing induction or maintenance therapy with bacillus Calmette-Gu\u00e9rin (BCG), and meeting certain criteria related to the stage and grade of the disease. Patients must also meet certain patient characteristics, such as having a WHO performance status of 0-4 and normal kidney and ureters on imaging CT scan within the past 12 months. Prior concurrent therapy is also taken into consideration.",
    "The sample is for a phase 3 clinical trial for post-traumatic stress disorder. The trial includes patients who have been hospitalized or not, veterans or civilians, and have had symptoms of PTSD for at least 12 months prior to giving consent. The trial involves the use of quetiapine fumarate and a placebo. The eligibility criteria include not having a history of psychotic conditions and not having previously tried quetiapine or other anti-psychotics. Patients taking prohibited medications such as mood stabilizers or those with substance abuse are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking at the effectiveness of nifedipine (adalat, baya1040) in treating essential hypertension in Japanese male or female patients who are at least 20 years old. The patients must have been treated with Adalat CR 40 mg od and at least one other antihypertensive drug (other than Ca antagonists) for 4 weeks or more before entering the study. The inclusion criteria also includes being an outpatient. The exclusion criteria includes patients with a sitting diastolic blood pressure (DBP) of 110 mm Hg or more, and patients with secondary hypertension or hypertensive emergency.",
    "The sample is a phase 3 clinical trial for seasonal allergic rhinitis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require participants to be at least 12 years old, have a documented history of SAR, and have a positive skin-prick test response to an appropriate seasonal allergen. Participants must also be clinically symptomatic at the screening and baseline visits, in good health, and free of any clinically significant disease that would interfere with the study evaluations. The exclusion criteria include a history of severe local reactions to skin testing, chronic use of inhaled or systemic corticosteroids for asthma, and allergies to more than two classes of medications. Participants with nasal structural abnormalities or who are dependent on certain medications are also excluded.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the disease thromboembolism. The icd-10 codes associated with the disease are listed. The trial involves two drugs, dabigatran and warfarin. The eligibility criteria for the trial are listed, including inclusion criteria such as having had an acute symptomatic deep vein thrombosis or pulmonary embolism within the past 3-12 months, and exclusion criteria such as having an excessive risk of bleeding or severe renal impairment.",
    "The sample is a phase 3 clinical trial for prostate cancer and male erectile disorder. The trial includes patients with stage I or II prostate cancer and requires them to undergo BNS-RAP surgery. The trial involves the use of two drugs, sildenafil citrate and alprostadil. The eligibility criteria include having a SHIMS-5 score of at least 22, maintaining follow-up care at COH for 18 months, and being willing to participate in the study for a minimum of 18 months. The exclusion criteria include having metastatic disease, coronary artery disease on nitrate therapy, and a Gleason score of 8 or higher on post-operative pathological sample prior to randomization.",
    "The sample is a phase 3 clinical trial for patients diagnosed with bronchial asthma, regardless of type. The trial is for males and females aged 5-15 years old who are able to inhale with turbuhaler and diskus. The trial requires patients who require treatment with inhaled steroids and have poorly controlled asthma. Patients who are already treated with inhaled GCS should have at least 3 months prehistory of asthma before obtaining the written informed consent. The trial has various exclusion criteria, including the use of regular systemic steroids within 30 days before the observation period, respiratory infections, and concurrent serious diseases of liver, kidney, heart, or other complications. Patients with known or suspected allergy to budesonide, fluticasone, or lactose contained in the investigational product are also excluded. Additionally, patients who are pregnant or planning to be pregnant during the study period, patients whose legal representative/caregiver is involved in the planning and conduct of the study, and other subjects who are considered inappropriate to participate in this study as judged by the investigator are excluded.",
    "The sample is a phase 3 clinical trial for various lipid metabolism disorders, including hypercholesterolemia and hyperlipoproteinemia type II. The trial is testing the effectiveness of the drug mipomersen compared to a placebo. The eligibility criteria for participants include a diagnosis of Homozygous Familial Hypercholesterolemia, stable lipid-lowering therapy for 12 weeks, stable weight for 6 weeks, and a stable low-fat diet for 8 weeks. Participants with significant health problems in the recent past, such as heart attack, stroke, blood disorders, cancer, or digestive problems, are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for patients with adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, or stage IV prostate cancer. The trial aims to test the effectiveness of the drugs docetaxel and prednisone in treating patients with progressive systemic disease despite castrate levels of testosterone due to orchiectomy or LHRH agonist. The eligibility criteria include having evidence of progressive metastatic disease, a Gleason sum based on biopsy or TURP, and meeting specific requirements for measurable and non-measurable disease. Patients must also have demonstrated evidence of progressive disease since the most recent change in therapy and have no prior cytotoxic chemotherapy or anti-angiogenesis agents. Additionally, patients must meet certain health criteria, such as having an ECOG performance status of 0-2 and ANC \u2265 1500/\u03bcL.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking at the effectiveness of the drugs doxorubicin, cyclophosphamide, and docetaxel. The eligibility criteria for the trial include women with large resectable or locally advanced breast cancer, measurable disease, no prior surgery other than biopsy, and no prior chemotherapy or radiation therapy. Patients must also be between the ages of 18 and 70, have a Karnofsky Performance score of at least 70%, and have adequate bone marrow, liver, and renal function. Patients with advanced pulmonary disease, peripheral neuropathy greater than grade 2, evidence of distant metastases, a history of breast cancer or another malignancy within the past 5 years, or who are pregnant or lactating are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and depression. The trial includes patients aged 18 to 65 years old who have been diagnosed with bipolar I or bipolar II disorder and are currently experiencing depression. The trial excludes patients with other Axis I disorders, a history of non-response to treatment, or those who pose a serious suicidal or homicidal risk. Pregnant or lactating patients are also excluded. The trial involves the use of the drug quetiapine fumarate (seroquel\u2122) as a mood stabilizer. The eligibility criteria for the trial include being an outpatient and having no clinically relevant disease or clinical finding.",
    "The sample is a phase 3 clinical trial for patients with metastatic renal cell carcinoma. The trial includes patients who have previously received sunitinib therapy and have documented radiological or clinical progression of the disease. The trial excludes patients with metastatic CNS from RCC, those who discontinued Sutent therapy due to intolerance, and those who have received prior systemic therapy for mRCC other than sunitinib. The trial also requires at least one measurable lesion per RECIST criteria and excludes lesions that have been previously irradiated or embolized. The trial involves the use of two drugs, sorafenib and temsirolimus, and has specific eligibility criteria that must be met for patients to participate.",
    "The sample is a phase 3 clinical trial for patients with biliary tract, gallbladder, or ampullary carcinoma that is unresectable and locally advanced, recurrent, or metastatic. The trial is testing the effectiveness of the drugs cisplatin and gemcitabine hydrochloride. The eligibility criteria include having a performance status of ECOG 0-2, a life expectancy of at least 3 months, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must not have brain metastases, unresolved biliary tract obstruction, or other severe or uncontrolled systemic diseases. They must also not have had prior gemcitabine hydrochloride or cisplatin chemotherapy, except for low-dose radiosensitizing chemotherapy in conjunction with radiotherapy. Prior curative surgery is allowed, but only if there is evidence of nonresectable disease relapse requiring systemic chemotherapy. Patients must have recovered from all prior therapies and must not be receiving any other concurrent, curative anticancer therapy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia and schizoaffective disorder. The trial involves the drug lurasidone hcl and includes a list of icd-10 codes for the diseases being treated. The eligibility criteria for the trial include completing a previous study and meeting certain BMI requirements, while exclusion criteria include being at risk of harm to oneself or others.",
    "The sample is a phase 3 trial for the treatment of major depressive disorder. The trial includes patients who have been diagnosed with major depressive disorder and the drugs being tested are aprepitant and a placebo (unspecified). The eligibility criteria for the trial are not specified in the sample. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of gastrointestinal stromal tumor. The trial is looking at the effectiveness of imatinib mesylate in patients who have undergone complete resection of the primary tumor and meet certain criteria related to tumor size, mitotic rate, and staining positive for Kit (CD117). Patients must also meet certain eligibility criteria related to age, performance status, hematopoietic, hepatic, renal, cardiovascular, and other medical conditions. Prior to the trial, patients cannot have received prior chemotherapy or molecular targeted or biologic therapy. The sample includes a detailed list of eligibility criteria related to disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for heart failure, congestive. The trial includes patients who have dyspnea at rest or with minimal exertion, fluid overload, and estimated creatinine clearance between 20-60 mL/min. The trial also requires patients to have worsening renal function and anticipated need for IV diuretic treatment for at least 48 hours after the start of study drug. The trial excludes patients who have had IV radiographic contrast within 14 days, IV vasodilators within 6 hours, serum potassium <3.5 meq/L, ongoing or planned therapy for heart failure with mechanical circulatory or ventilatory support, ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis, rapidly progressive acute renal failure, evidence of acute tubular necrosis or post-obstructive nephropathy or other exogenous causes of acute kidney injury unrelated to heart failure, severe pulmonary disease, significant stenotic mitral or aortic valvular disease, heart transplant recipient or admitted for cardiac transplantation or LVAD surgery, any major surgery within 2 weeks prior, evidence of acute coronary syndrome in the 2 weeks prior, Hgb <8 g/dL, Hct <25%, or active bleeding requiring transfusion, acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy, known hepatic impairment, non-cardiac pulmonary edema, temperature >38\u00b0C, sepsis or active infection requiring IV anti-microbial treatment, administration of an investigational drug or device within 30 days, current or anticipated therapy with atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole, administration of any vasopressor or inotropic drug within 72 hours, history of seizure (except febrile seizure), stroke within 2 years, history of brain tumor of any etiology, brain surgery within 2 years, encephalitis/meningitis within 2 years, history of penetrating head trauma, closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years, history of or at risk for alcohol withdrawal seizures, advanced Alzheimer's disease, and advanced multiple sclerosis.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of metastatic colorectal cancer. The trial involves the use of drugs such as bevacizumab, erlotinib, and low dose capecitabine. The eligibility criteria for the trial include having untreated metastatic colorectal carcinoma, being over 18 years old, having measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST criteria), having an ECOG performance status of 0 or 1, having a life expectancy of more than 3 months, having adequate haematological, renal and liver function, having tumor tissue available for determination of KRAS mutational status, and having blood sample and paraffin embedded tumor tissue for translational research. The exclusion criteria include having received adjuvant therapy within 6 months, having CNS metastases, and having clinically significant atherosclerotic vascular disease.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the disease of osteoporosis. The trial includes a list of icd-10 codes associated with the disease. The trial involves the use of several drugs, including odanacatib, placebo, vitamin d3, and calcium supplement. The eligibility criteria for participants include being postmenopausal for 3 years, having a BMD t-score within a specific range, having two hips that can be evaluated by DXA and QCT, and being ambulatory. Exclusion criteria include previous hip fracture, multiple clinical vertebral fractures, prior treatment with certain bone-affecting agents, metabolic bone disorders, and certain medical conditions such as renal stones, Parkinson's disease, multiple sclerosis, or active parathyroid disease.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of osteoporosis. The trial involves the drug zoledronic acid and has a list of icd-10 codes associated with the disease. The eligibility criteria for the trial includes males between the ages of 25-85 who are not current users of certain bisphosphonates and do not have a history of severe liver, kidney, or eye disease. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of Parkinson's disease. The trial includes participants who have been diagnosed with idiopathic Parkinson's disease and have received prior therapy with L-dopa for at least one year. Participants must also be experiencing motor fluctuations with or without dyskinesias and have a Hoehn & Yahr stage between 2.5 and 4 when in the \"on\" state. The trial involves the use of preladenant and a placebo. Participants must meet certain inclusion criteria, such as being able to maintain an accurate symptom diary and adhere to dose and visit schedules, and must not meet certain exclusion criteria, such as having a form of drug-induced or atypical parkinsonism, a cognitive impairment, or a history of repeated strokes or head injuries.",
    "The sample is a phase 3 clinical trial for patients with chronic pain associated with various conditions such as cancer, diabetic peripheral neuropathy, and back pain. The trial is testing the effectiveness of fentanyl buccal tablets for alleviating breakthrough pain episodes. Patients must be using a stable dose of around-the-clock opioid therapy for at least 7 days prior to enrollment and must meet certain eligibility criteria, such as having an average pain intensity score of 6 or less and experiencing 1 to 4 breakthrough pain episodes per day. Patients must also be willing and able to self-administer the study drug and comply with study restrictions. There are various exclusion criteria, such as uncontrolled or rapidly escalating pain, allergies or contraindications to the study drug, and recent history of substance abuse.",
    "The sample is a phase 3 clinical trial for patients with chronic kidney disease who require hemodialysis. The trial is testing the effectiveness of soluble ferric pyrophosphate (sfp) as a treatment option. The eligibility criteria for the trial include being an adult over 18 years old, having undergone chronic hemodialysis for at least 4 months, and having received IV iron therapy between 6 months and 2 weeks prior to enrollment. Other criteria include having a mean screening Hgb level between 9.5 and 11.5 g/dL, mean screening transferrin saturation (TSAT) between 15% and 40%, and mean screening serum ferritin between 200 and 800 \u00b5g/L. Patients must also meet certain exclusion criteria, such as having a living kidney donor identified or scheduled transplant, having a femoral or non-tunneled catheter for dialysis, or having received a total of > 800 mg IV iron during the 8 weeks prior to enrollment. The trial is divided into three stages, each with its own set of inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the drugs vildagliptin and placebo. The eligibility criteria for the trial include not currently being on drug therapy for type 2 diabetes and meeting certain blood glucose criteria. Exclusion criteria include a history of type 1 diabetes, significant diabetic complications, and serious cardiovascular events within the past 6 months. Other exclusion criteria may also apply. The diseases being studied are limited to diabetes mellitus, type 2, and the corresponding ICD-10 codes are provided.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on type 2 diabetes mellitus and includes a list of ICD-10 codes for the disease. The trial involves testing the effectiveness of two drugs, placebo/teneli (teneligliptin) + pio (pioglitazone) and teneli/teneli + pio. The eligibility criteria for the trial include patients who are between 20-75 years old, under dietary management and taking therapeutic exercise for diabetes for over 12 weeks before administration of the investigational drug, have an HbA1c level between 6.5% and 10.0%, and have taken Thiazolidinedione for diabetes over 16 weeks before administration of the investigational drug. The exclusion criteria include patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes, patients who are accepting treatments of arrhythmias, patients with serious diabetic complications, patients who are excessive alcohol addicts, patients with severe hepatic disorder or severe renal disorder, patients who are pregnant, lactating, and probably pregnant patients, and patients who cannot agree to contraception.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic hepatitis B. The trial involves the drug telbivudine (ldt). The eligibility criteria for the trial include having completed a previous qualifying Idenix-Sponsored trial with telbivudine and not having been discontinued from the previous study. The exclusion criteria include being pregnant or breastfeeding and being co-infected with hepatitis C, hepatitis D, or HIV. Other protocol-defined inclusion and exclusion criteria may also apply. The diseases are listed as 'chronic hepatitis b' and the icd-10 codes associated with the disease are listed as [\"['B18.0', 'B18.1', 'B18.2', 'B18.8', 'B18.9']\"].",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of two drugs, zolpidem mr and zolpidem, in treating sleep initiation and maintenance disorders and sleep disorders. The diseases are listed along with their corresponding ICD-10 codes. The eligibility criteria for the trial are also provided, including the inclusion criteria of having a clinical diagnosis of nonorganic insomnia and being able to swallow tablets, and the exclusion criteria of having allergic reactions to zolpidem or serious cardiac, hepatic, or renal disorders.",
    "The sample is a phase 3 clinical trial for ART-experienced adults with HIV-1 infection. The trial involves the use of drugs such as gsk1349572 and raltegravir, as well as placebos. The eligibility criteria include being at least 18 years old, having documented resistance to two or more different classes of antiretroviral agents, and being INI-na\u00efve. Exclusion criteria include having an active AIDS-defining condition, moderate to severe hepatic impairment, and recent history of gastrointestinal bleeding. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 trial related to contraception and ovulation inhibition. The diseases involved are contraception, ovulation inhibition, and oral contraceptives. The icd-10 codes associated with these diseases are also provided. The drugs used in the trial are ee20/drsp (bay86-5300), ee20/drsp (bay86-5300), and ee20/drsp (yaz, bay86-5300). The eligibility criteria for the trial include healthy women between 18 and 45 years of age who are requesting oral contraception. Smokers should not be over 35 years of age. The use of steroidal oral contraceptives or any drug that could alter oral contraception metabolism is prohibited during the study.",
    "The sample is a phase 3 clinical trial for participants with type 2 diabetes mellitus. The trial involves testing the effectiveness of various drugs, including ly2189265, sulfonylureas, biguanides, alpha-glucosidase inhibitor, thiazolidinedione, and glinides. The eligibility criteria for participants include having a diagnosis of type 2 diabetes mellitus, being on a stable dose of one of the listed drugs for at least 3 months before screening, having a qualifying HbA1c value of 7.0% to 11.0% at screening, and having a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared. Exclusion criteria include having a diagnosis of type 1 diabetes, previously being treated with any other glucagon-like peptide-1 (GLP-1) analog within the 3 months before screening, currently taking insulin or having had previous insulin treatment within the 3 months before screening, having clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, and having a self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC).",
    "The sample is a phase 3 clinical trial for the treatment of generalized anxiety disorder (GAD) using duloxetine hydrochloride and placebo. The trial includes patients who suffer from GAD without major depressive disorder (MDD) and excludes patients with other primary diagnoses, a history of MDD within the past 6 months, panic disorder, post-traumatic stress disorder (PTSD), eating disorders within the past year, obsessive-compulsive disorder (OCD), bipolar affective disorder, psychosis, factitious disorder, or somatoform disorders during their lifetime. Patients with a history of alcohol or psychoactive substance abuse or dependence within the past 6 months, serious medical illnesses, acute liver injury, or severe cirrhosis are also excluded. The eligibility criteria for inclusion and exclusion are clearly defined. The diseases are listed as anxiety disorders, and the icd-10 codes associated with the diseases are also provided.",
    "The sample is a phase 3 clinical trial for HIV infection using the drugs truvada and raltegravir. The eligibility criteria include being 18 years or older, having a documented HIV-1 infection, having a viral load of less than 50 copies/mL, having a CD4 cell count of more than 50 cells/mm3, and being on a stable ART with at least 3 licensed agents, one of which being EFV, for at least 12 weeks. The trial also requires participants to have an estimated glomerular filtration rate of more than 50 ml/min and to have symptomatic toxicity associated with EFV after at least 12 weeks of therapy. Exclusion criteria include being infected with HIV-2, having acute viral hepatitis, having chronic hepatitis B and/or C with AST and/or ALT >5 x ULN, and having received any investigational drug within 30 days prior to the trial drug administration.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone. The trial is looking for participants who meet the DSM-IV criteria for schizophrenia and are experiencing an acute schizophrenic episode with a PANSS total score of 70 or higher. Participants must be admitted to the hospital for treatment and agree to voluntary hospitalization for at least the first 7 days of the study. Female participants must meet certain criteria for birth control and have a negative pregnancy test. Participants or their representatives must sign an informed consent document. Exclusion criteria include pregnancy or breastfeeding, first antipsychotic treatment ever, hypersensitivity to paliperidone or risperidone, and relevant history of certain diseases or substance dependence.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) and involves a list of drugs including qva149, nva237, qab149, and placebo. The trial has eligibility criteria for inclusion and exclusion, including age, smoking history, diagnosis of moderate to severe COPD, and certain pulmonary and cardiovascular conditions. The trial also excludes patients with a history of asthma, lung cancer, and alpha-1 antitrypsin deficiency, among other criteria. The trial may have additional inclusion and exclusion criteria as defined by the protocol.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone er. The trial is looking for patients who have been newly diagnosed with schizophrenia and have not taken any antipsychotics for at least one month prior to screening. Patients must have a PANSS score of 80 to 120 at screening and be healthy based on physical and laboratory examinations. Women must have a negative pregnancy test and agree to use birth control throughout the study. Exclusion criteria include serious medical conditions, high risk for adverse events or self-harm, inability to swallow the medication whole, abnormal biochemistry results, substance dependence, and positive urine drug examination.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 3, and a list of diseases being studied, which are atrial fibrillation and vascular risk. The table also includes a list of ICD-10 codes associated with the diseases. The drug being studied is clopidogrel (sr25990c). The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age, medical history, and other factors. The sample also includes specific exclusion criteria, such as recent coronary stent procedure, intracerebral hemorrhage, and ongoing alcohol abuse.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease, with the drug Aricept (donepezil) being tested. The trial has eligibility criteria for both patients and caregivers, including age range, diagnostic evidence of Alzheimer's disease, and stable medication use. Patients must have a caregiver who can accompany them to all visits and observe for adverse events. Exclusion criteria include certain medical conditions, psychiatric disorders, and drug or alcohol abuse. The trial also allows for certain concomitant medications and has psychometric test criteria for caregivers.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who are experiencing inadequate glycemic control. The trial is testing the effectiveness of the drug sitagliptin. The eligibility criteria include having a historical diagnosis of type 2 diabetes mellitus, being renally impaired, having a BMI between 20 and 45 kg/m2, and having a fasting C-peptide level of at least 0.8 ng/mL. The HbA1c level must be between 7.0% and 10.0%. Exclusion criteria include a history of cancer, treated diabetic gastroparesis, biliary disease or pancreatitis, significant gastrointestinal surgery, recent cardiovascular or cerebrovascular disease, HIV infection, abnormal liver function, pregnancy or lactation, allergy to study medications, and receipt of investigational drugs within a certain time frame.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who have consented to participate and are over 18 years old with a life expectancy of at least 5 years. Patients must have a diagnosis of adenocarcinoma of the rectum and the tumor must be considered amenable to curative resection. The trial includes a list of drugs such as capecitabine, fluorouracil, and oxaliplatin. The eligibility criteria include various medical tests and requirements such as ANC count, platelet count, and adequate hepatic function. Patients with prior malignancies are eligible if they have been disease-free for more than 5 years. The exclusion criteria include findings of metastatic disease, rectal cancers other than adenocarcinoma, and history of invasive rectal malignancy.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial includes patients who have a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) of at least 30% and less than 80% of the predicted normal, and a post-bronchodilator FEV1/ Forced Vital Capacity (FVC) of less than 0.70 at screening. Patients must also have a smoking history of at least 10 pack years and be symptomatic according to daily electronic diary data. The trial excludes pregnant or nursing women, patients with clinically relevant laboratory abnormalities or significant conditions, patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction, moderate to severe renal impairment or urinary retention, and patients receiving prohibited medications. Other protocol-defined inclusion/exclusion criteria apply and can be found in the study protocol.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes the drugs saredutant (sr48968), escitalopram, and a placebo. The eligibility criteria for the trial include being an outpatient with recurrent major depressive disorder, having symptoms of the current depressive episode for at least 30 days but no more than 2 years, not having mild depression, not having a significant suicide risk, not lacking sexual activity, not having other psychiatric conditions that would obscure the results of the study, not having a history of failure to respond to antidepressant treatment, and not being pregnant or breastfeeding. The sample also includes a disclaimer that the information provided is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "The sample is a phase 3 clinical trial that involves patients with various types of leukemia and myelodysplastic syndromes. The trial is testing the effectiveness of three drugs - tacrolimus, methotrexate, and sirolimus. The eligibility criteria for the trial include having a 6/6 HLA-matched sibling who is willing to donate peripheral blood stem cells, having a certain level of performance status, being able to take oral medications, and meeting certain medical criteria. Exclusion criteria include having a prior transplant, being seropositive for HIV, having uncontrolled infections, being pregnant or breastfeeding, having abnormal kidney or liver function, having lung or cardiac disease, having high cholesterol or triglyceride levels, having a history of allergy to sirolimus, requiring voriconazole, currently receiving another investigational drug, or having a history of cancer within the past 5 years.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients aged 18 to 65 years with a documented diagnosis of major depressive disorder. The trial excludes patients with a DSM IV Axis I disorder other than MDD within 6 months of enrollment, patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status, and patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrollment. The trial involves the use of two drugs, quetiapine sr and escitalopram.",
    "The sample is a phase 3 clinical trial that involves various diseases such as adult malignant mesenchymoma, childhood rhabdomyosarcoma, and nonmetastatic childhood soft tissue sarcoma. The trial uses drugs such as vincristine sulfate, cyclophosphamide, and topotecan hydrochloride. The eligibility criteria for the trial include having a histologically proven disease of certain types, being within a certain age range, not having received prior chemotherapy or radiotherapy, and meeting certain medical criteria such as having normal bilirubin and creatinine levels. The trial also requires fertile patients to use effective contraception and prohibits pregnant or nursing individuals from participating.",
    "The sample is a phase 3 clinical trial for patients with orthostatic hypotension and Parkinson's disease. The trial is testing the effectiveness of the drug droxidopa. The eligibility criteria include being 18 years or older, having a clinical diagnosis of Parkinson's disease and symptomatic neurogenic orthostatic hypotension, and meeting certain baseline measurements. Exclusion criteria include having a low score on the mini-mental state examination, using certain medications, having certain medical conditions, and more. Patients must provide written informed consent to participate in the study.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been receiving basal insulin and a stable dose of 0 to 3 oral antihyperglycemic medications for at least 90 days prior to screening. The trial is testing the effectiveness of ly2605541 and insulin glargine as treatments for diabetes. The eligibility criteria include having a hemoglobin A1c less than or equal to 9.0%, a body mass index less than or equal to 45.0 kilograms per square meter, and practicing reliable birth control for at least 6 weeks prior to screening. The exclusion criteria include having routinely used insulin glargine twice daily in the 90 days prior to the study, having used certain medications within 90 days prior to screening, and having certain medical conditions such as severe hypoglycemia or cardiac disease with functional status that is New York Heart Association Class III or IV.",
    "The sample is a clinical trial for patients with schizophrenia and cognitive effects. The trial is in phase 2/phase 3 and involves the drugs cyp-1020 and risperidone. The eligibility criteria include being between 18-50 years old, exhibiting symptoms of schizophrenia for at least one year but not more than 20 years, and currently experiencing an acute exacerbation of schizophrenia. The trial also requires a sufficient clinical response to at least one previous course of an anti-psychotic agent prescribed at a generally recognized therapeutic dose. The exclusion criteria include being pregnant or breastfeeding, having symptoms of schizophrenia for more than 20 years, and having a history of neuroleptic malignant syndrome. The trial also excludes patients with certain medical conditions or allergies to the drugs being tested.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed. The trial involves two drugs, sitagliptin phosphate and a placebo comparator. The eligibility criteria for the trial are also listed, including specific laboratory results that patients must meet to be included in the trial, as well as exclusion criteria such as having type 1 diabetes or requiring insulin therapy within the past 12 months.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the use of the drug mitiglinide and a placebo. The eligibility criteria for the trial include a diagnosis of type 2 diabetes for at least 6 months, stable metformin usage for at least 4 months, and an HbA1c level between 7.5% and 10.5%. The trial excludes individuals who use chronic insulin or oral diabetic agents within the past 12 weeks, as well as those with acute or chronic conditions that could affect the evaluation of the trial's endpoint.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on head and neck neoplasms and involves a list of icd-10 codes for related diseases. The trial will test the effectiveness of the drugs pemetrexed, cisplatin, and placebo. The eligibility criteria for participants include having head and neck cancer that cannot be treated with surgery or other types of treatment, having a performance status of 0, 1, or 2, and having normal liver, kidney, and blood cell function. Participants must also be at least 18 years old and willing to sign a consent form. Exclusion criteria include having previously received treatment for cancer that has spread to other parts of the body, having a serious illness that may prevent completion of the study, and having certain types of cancer. Participants cannot take certain medications during the study.",
    "The sample is a phase 3 clinical trial for restless legs syndrome (RLS) and involves the use of ropinirole IR and CR drugs. The trial includes patients who have been diagnosed with RLS using IRLSSG diagnostic criteria and are currently being treated with a stable dose of ropinirole IR. The inclusion criteria also require patients to have RLS symptoms during the evening and/or night. Exclusion criteria include patients who require treatment for daytime RLS symptoms, have signs of secondary RLS, have clinically significant or unstable medical conditions, are receiving prohibited medications, have sleeping habits incompatible with the study design, are intolerant to ropinirole or other dopamine agonists, are pregnant or lactating, or are women of child-bearing potential who are not practicing an acceptable method of birth control.",
    "The sample is a phase 3 clinical trial for the treatment of myocardial infarction. The trial involves the drug clopidogrel (also known as iscover or plavix) and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having an acute STEMI within 6 hours and planned percutaneous coronary intervention, while exclusion criteria include having had thrombolytic therapy within 24 hours before randomization and having a contraindication to clopidogrel. The sample also includes a list of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for nonmetastatic anal cancer. The trial is testing the effectiveness of cisplatin and fluorouracil as treatments. The eligibility criteria for patients include having histologically proven nonmetastatic anal cancer, being at stage II or III, having tumors at least 4 cm in greatest dimension and/or tumors with lymph node invasion that are nonmetastatic by ultrasound, and meeting certain patient characteristics such as being 80 years old or younger and having a WHO performance status of 0 or 1. Patients cannot have had prior surgery to remove the tumor or prior biologic, chemotherapy, endocrine therapy, or pelvic or inguinal radiotherapy. The sample also includes specific disease characteristics and other medical criteria that patients must meet to be eligible for the trial.",
    "The sample is a phase 3 clinical trial for individuals between the ages of 18 and 65 who have a clinical history of significant allergic rhinoconjunctivitis to grass, with or without asthma. The trial includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs that will be used in the trial. The eligibility criteria include having a positive skin prick test response to Phleum pratense, a specific IgE against Phleum pratense, and an FEV1 >=70% of predicted value. Participants must also be willing to adhere to dose and visit schedules and use a medically acceptable form of birth control if female and of childbearing potential. The exclusion criteria include a history of severe asthma, anaphylaxis with cardiorespiratory symptoms, chronic urticaria and angioedema, and chronic sinusitis during the 2 years prior to the Screening Visit, among others.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the diseases hepatitis B and cirrhosis. The icd-10 codes associated with these diseases are also listed. The drug being studied is a combination of ldt (telbivudine) and lamivudine. The eligibility criteria for the trial state that patients with chronic hepatitis B and evidence of cirrhosis, who are between the ages of 18 and 70, may be eligible to participate.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The trial includes the drugs safinamide and placebo. The eligibility criteria for the trial include completing 24 weeks of treatment in a previous study, being compliant with taking study medication, and signing an informed consent form. Exclusion criteria include experiencing clinically significant adverse events, showing deterioration during a previous study, and discontinuing the previous study prematurely without returning for scheduled evaluations. The sample also includes the ICD-10 code for Parkinson's disease.",
    "The sample is a phase 3 clinical trial for the treatment of active acromegaly. The trial requires patients to have a documented diagnosis of active acromegaly and be adequately treated with a stable dose of Octreotide LAR for at least 6 months prior to study entry. The trial will use lanreotide (autogel formulation) as the treatment, with the duration of treatment ranging from 24-56 weeks depending on the dose interval. The eligibility criteria include giving written informed consent, having a diagnosis of active acromegaly, and meeting specific IGF-1 and GH level requirements. The exclusion criteria include having had pituitary surgery within 6 months prior to study entry or receiving radiotherapy for acromegaly within three to five years prior to study entry.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of epilepsy. The icd-10 codes associated with the disease are listed, along with the drug being tested, which is pregabalin. The eligibility criteria for the trial are also provided, including inclusion criteria such as having completed a previous protocol and having a diagnosis of epilepsy with partial seizures, and exclusion criteria such as early withdrawal from the previous protocol or having experienced an episode of status epilepticus or primary generalized epilepsy.",
    "The sample is a clinical trial for lung cancer patients in phase 3. The trial is testing the effectiveness of the drugs docetaxel and vandetanib. The eligibility criteria for the trial include having a confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer and having had 1st line anti-cancer therapy. Patients who have received treatment with docetaxel or 2nd line anti-cancer therapy are not eligible. Additionally, patients with a history of uncontrolled irregular heartbeat or high blood pressure that has not been controlled with medication are also not eligible. The trial has inclusion and exclusion criteria that must be met in order to participate.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis. The trial includes patients who have been diagnosed with plaque-type psoriasis at least 6 months prior to the study, have psoriasis covering at least 10% of their body, and have a Psoriasis Area and Severity Index (PASI) score of 12 or greater and a Physician's Global Assessment (PGA) score of 3 or greater. Patients must also be suitable for phototherapy or systemic treatment for psoriasis and have failed to respond to or have a condition which prevents the use of cyclosporine, methotrexate (MTX) or psoralen plus ultraviolet light A (PUVA). The trial excludes patients who currently have nonplaque forms of psoriasis, have current drug-induced psoriasis, have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or IL-23, have received phototherapy or any systemic medications/treatments that could affect psoriasis or PASI evaluation within 4 weeks of the first administration of study agent, or have used a biologic within the previous 3 months.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of asthma. The icd-10 codes associated with the disease are listed, along with the drugs being tested - montelukast sodium and placebo. The eligibility criteria for the trial are also provided, including inclusion criteria for individuals with acute asthma and exclusion criteria for women of childbearing age and those with a history of Chronic Obstructive Pulmonary Disease (COPD).",
    "The sample is a phase 3 clinical trial for major depressive disorder and depression. The trial includes patients who have had an inadequate response to no more than one antidepressant and are out-patients at enrollment and randomization. The trial excludes patients with a lifetime history of bipolar disorder, psychotic disorder, or post-traumatic stress disorder, as well as those with a history of suicide attempts in the past year or with a significant history of risk of suicide or homicide. Additionally, patients with a history of renal insufficiency or impairment or conditions that could affect absorption or metabolism of the investigational product in this patient population are excluded. The trial involves the drugs tc-5214 and placebo, and the eligibility criteria include provision of signed and dated informed consent before initiation of any study-related procedures.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the disease diabetes, with a list of icd-10 codes associated with the disease. The drug being tested is mitiglinide. The eligibility criteria for the trial includes patients with type 2 diabetes who have inadequate control of blood glucose with diet and/or exercise therapy. However, patients with type 1 diabetes, severe diabetic complications, severe ketosis, diabetic coma or precoma, severe hepatic diseases, severe renal diseases, severe hypertension, severe cardiac disease, pregnant women or women who want to become pregnant during the study period are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with hematologic malignancies at intermediate or high risk of tumor lysis syndrome (TLS). The trial is testing the effectiveness of febuxostat and allopurinol as treatments for TLS. The eligibility criteria include being scheduled for first cytotoxic chemotherapy cycle, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, and a life expectancy of more than 1 month. The exclusion criteria include hypersensitivity to febuxostat or allopurinol, sUA levels \u2265 10 mg/dL at randomization, receiving any urate lowering therapy within 30 days prior to randomization, severe renal and/or hepatic insufficiency, and diagnosis of LTLS or CTLS at randomization. The diseases being studied are limited to tumor lysis syndrome, and the icd-10 codes associated with it are E88.3.",
    "The sample is a phase 3 clinical trial for dry eye disease. The trial includes patients who are at least 18 years old and have a patient-reported history of dry eye in both eyes. The trial also requires patients to have used artificial tears within the past 30 days. The trial has inclusion and exclusion criteria, including the requirement for patients to avoid wearing contact lenses for 7 days prior to the first visit and for the duration of the study. Patients with certain ocular conditions, a history of immunodeficiency disorder, or a history of alcohol and/or drug abuse are excluded from the trial. The trial involves the use of two drugs, lifitegrast and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of gastric carcinoma. The trial includes two parts: a Pilot Part and a Randomized Part. The Pilot Part includes subjects who have received one prior regimen for gastric carcinoma and developed disease progression or recurrence. The Randomized Part includes subjects who have received one prior regimen for gastric carcinoma and defined as progression disease, and have documented amplification of ErbB2 by fluorescence in situ hybridization (FISH) in primary or metastatic tumor tissue. The trial involves the use of two drugs, lapatinib and paclitaxel. The eligibility criteria for both parts of the trial include signed informed consent, specific disease criteria, left ventricular ejection fraction (LVEF) within institutional range of normal, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1, and adequate organ function. The trial also includes exclusion criteria such as pregnancy or lactation, unresolved or unstable, serious toxicity from prior cancer treatment, and concurrent disease or condition that would make the subject inappropriate for study participation.",
    "The sample is a phase 3 clinical trial for advanced non-small cell lung cancer. The trial includes patients with metastatic or locally advanced lung cancer, both at first diagnosis or with disease recurrence after former surgery. The trial requires patients to have at least one target or non-target lesion according to RECIST criteria, and to meet certain eligibility criteria such as being male or female over 18 years of age, having an ECOG PS of 0 or 1, and having a life expectancy of more than 3 months. The trial also has exclusion criteria, such as prior exposure to agents directed at the HER axis, any unstable systemic disease, and any other malignancies within the past 5 years. The trial involves the use of drugs such as erlotinib, cisplatin, and gemcitabine, and requires patients to meet certain laboratory criteria such as having neutrophils > 1,500 mm3, platelets > 100,000 mm3, and hemoglobin > 9 g/dL. The trial also requires patients to have effective contraception if the risk of conception exists, and to sign written informed consent.",
    "This sample is for a phase 3 clinical trial for the treatment of psoriasis. The trial is looking at the effectiveness of two drugs, clobetasol propionate spray 0.05% and calcitriol ointment, for patients with moderate to severe plaque psoriasis. The eligibility criteria for the trial include a diagnosis of moderate to severe plaque psoriasis with 3% to 20% treatable body surface area and an overall disease severity of at least 3 (moderate). The exclusion criteria include psoriasis involving only the scalp, groin, axillae, and/or other intertriginous areas, and surface area involvement too large (>20% BSA). The icd-10 codes for psoriasis are also included in the table.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the diseases of optic neuritis and multiple sclerosis, with corresponding ICD-10 codes. The trial involves the use of the drugs simvastatin and placebo. The eligibility criteria for the trial include having acute optic neuritis, abnormal contrast sensitivity score, symptom duration of maximum 4 weeks, being between 18 and 59 years old, being physically and mentally able to participate for 6 months, and signing a written consent form. Exclusion criteria include having had optic neuritis in the same eye before, being pregnant or nursing, not using contraception if fertile, contemplating pregnancy during the study, having received steroid or immune-suppressor treatment within a certain time frame, having active liver disease or kidney failure, having myopathy, hyperthyroidism, diabetes mellitus, alcoholism, or taking fibrates or statin treatment for other diseases, and participating in other studies simultaneously.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed. The drug being tested is valsartan plus hydrochlorothiazide. The eligibility criteria for the trial are also listed, including inclusion criteria of having severe hypertension and exclusion criteria such as having a history of stroke or heart failure, liver or kidney disease, or poor glucose control. There may be additional exclusion criteria defined by the protocol.",
    "The sample is a phase 3 clinical trial for cardiovascular disease. The trial involves the use of the drugs eptifibatide and placebo. The eligibility criteria for the trial include being over 18 years old, having stable or unstable angina pectoris, and meeting certain hemodynamic conditions. The trial also requires angiographic evidence of a de novo lesion > 50% requiring implantation of two DES in overlapping with a total stent length > 33 mm and reference vessel diameter between 2.5 and 4.0 mm. The exclusion criteria include having ongoing or recent unstable coronary artery disease, administration of any GP IIb/IIIa inhibitors during the previous 2 weeks, and having a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or sensitivity to contrast which cannot be adequately pre-medicated. The angiographic exclusion criteria include DES implantation in a chronic total occlusion or for the treatment of in-stent restenosis, treatment of lesions where the operator feels necessary the usage of rotactional atherectomy, vessel size < 2.25 mm or > 5 mm, and previous implantation of a bare/DES in the target lesion.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial is looking for adult participants between the ages of 18 and 80 who have had active rheumatoid arthritis for at least 6 months and have received treatment for it on an outpatient basis, but have not responded well to at least one anti-TNF alpha therapy. Participants must have also received methotrexate for at least 12 weeks prior to screening at a stable dose. The trial requires participants to have at least 8 swollen and tender joints and radiographic evidence of at least one joint with a definite erosion due to RA. Participants of reproductive potential must be using reliable contraceptive methods. There are several exclusion criteria, including bone or joint surgery within 8 weeks prior to screening, class IV functional status of RA, and previous treatment with rituximab or other cell-depleting therapies. Participants with significant uncontrolled concomitant diseases or a history of cancer are also excluded. Women who are pregnant or breastfeeding are not eligible to participate.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial involves two drugs, beclomethasone dipropionate hydrofluoroalkane hfa nasal aerosol and placebo nasal aerosol. The eligibility criteria for the trial include having a documented history of perennial allergic rhinitis, a demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test, and a minimum subject-reported reflective total nasal symptom score (rTNSS) of at least 6 (out of a possible 12). The exclusion criteria include a history of physical findings of nasal pathology, participation in any investigational drug study 30 days preceding screening visit, history of respiratory infection/disorder with 14 days preceding screening visit or during the run-in period, and use of any prohibited concomitant medications.",
    "The sample is a phase 3 clinical trial for the treatment of advanced stage non-small-cell lung carcinoma. The trial involves the use of two drugs, afatinib and erlotinib, and has a list of inclusion and exclusion criteria for eligible participants. Inclusion criteria include having measurable disease, adequate performance status, and being 18 years or older. Exclusion criteria include prior treatment with certain drugs, active brain metastases, and any other serious illness or dysfunction that could compromise patient safety or interfere with the evaluation of the test drug. The trial also requires written informed consent consistent with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drugs gemcitabine and carboplatin. The eligibility criteria for the trial include having a new diagnosis of NSCLC, Stage IIIB with a cytologically positive pleural or pericardial effusion or Stage IV, no prior chemotherapy for NSCLC, an ECOG Performance Status of 2, measurable disease, and being at least 3 weeks since major surgery. Exclusion criteria include prior radiation therapy to the thoracic area, active and ongoing systemic infection, prior radiation to greater than 25% of the bone marrow, an ECOG PS other than 2, and a known hypersensitivity to gemcitabine and carboplatin.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on chronic obstructive pulmonary disease and includes a list of ICD-10 codes for the disease. The trial involves several drugs, including qva149, tiotropium, and salbutamol/albuterol, as well as placebos for qva149 and tiotropium. The eligibility criteria for the trial include patients with moderate to severe stable COPD, a smoking history of 10 pack years, and a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 30 - 80%. Patients must also be able to use a computer mouse and display, and have an mMRC grade greater than 2. Exclusion criteria include patients with a history of long QT syndrome, Type I or uncontrolled Type II diabetes, recent COPD exacerbation or respiratory tract infection, any history of asthma, pulmonary lobectomy, lung volume reduction surgery, or lung transplantation, concomitant pulmonary disease, and patients requiring long term oxygen therapy. The sample also notes that other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 3 clinical trial for patients diagnosed with Major Depressive Disorder. The trial involves the use of two drugs, 323u66 (bupropion hydrochloride sustained release) and placebo. The eligibility criteria include having a HAM-D (17 items) total score of at least 16, being between 18 and 65 years old, and having a diagnosis of Major Depressive Disorder, Single Episode or Recurrent. Inclusion criteria also require patients to have been treated with marketed paroxetine (Paxil\u00ae) at 20mg/day to 40mg/day for 4 weeks and more at the start of the pretreatment phase. Exclusion criteria include having a complication of glaucoma, being pregnant or nursing, having a history of hypersensitivity to 323U66 and/or paroxetine, and having serious physical symptoms such as cardiac/hepatic/renal disorder or hematopoietic disorder. The trial involves multiple phases, and patients must meet certain criteria at each phase to continue in the trial.",
    "The sample is a phase 3 clinical trial for patients with advanced idiopathic Parkinson's disease whose symptoms are not adequately controlled with L-dopa. The trial is testing the effectiveness of two different forms of ropinirole, a drug used to treat Parkinson's disease. The eligibility criteria include modified Hoehn & Yahr criteria Stages II-IV, while the exclusion criteria include late stage advanced Parkinson's disease with incapacitating dyskinesias on a stable dose of L-dopa, significant and/or uncontrolled psychiatric, haematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or active malignancy, recent history of severe dizziness or fainting on standing, dementia, neurotic behaviour, crippling degenerative arthritis or limb amputations, prior or current major psychosis, recent history or current evidence of drug abuse or alcoholism, use of a dopamine agonist within 4 weeks of starting the study, and personal or family history of an allergic reaction to ropinirole.",
    "The sample is a phase 3 trial for patients with hypercholesterolemia and dyslipidemia. The trial involves the drug pitavastatin and requires patients to have completed 12 weeks of treatment in a previous study without experiencing any significant adverse events related to the drug. Patients must also be following a fat and cholesterol restrictive diet. Exclusion criteria include conditions that may cause secondary dyslipidemia, uncontrolled diabetes mellitus, abnormal pancreatic, liver, or renal function, abnormal serum levels of certain enzymes, and significant heart disease.",
    "The sample is a phase 3 clinical trial for the treatment of migraine disorders using the drug sumatriptan succinate. The trial includes patients with a diagnosis of migraine or cluster headache according to the International Classification of Headache Disorders, Version 2 (ICHD-II) and a history of migraine or cluster headache persisting for at least 6 months. Inclusion criteria also require patients to have experienced one to six attacks of moderate or severe headaches per month during the two months prior to enrollment. The trial has a list of exclusion criteria, including a history of hypersensitivity to any of the ingredients of 5-HT1B/1D receptor antagonists (e.g., triptans) or serious adverse events due to treatment with these drugs. Pregnant women, lactating mothers, women who may be pregnant, or women of childbearing potential using no appropriate contraceptive measures are also excluded. The trial requires written informed consent from the patient or their proxy consenter.",
    "The sample is a phase 3 clinical trial for kidney diseases. The trial includes patients who are 12-24 months post renal transplantation with stable transplant function and are receiving triple immunosuppression with cyclosporine, MMF, and daily steroids at study entry. The trial aims to test the effectiveness of methylprednisolone as a treatment for kidney diseases. The eligibility criteria include age less than 18 years, bone age of boys less than 15 years and girls less than 13 years, and first or second kidney transplant, living or cadaver kidney donation. The exclusion criteria include irreversible rejection of former transplant within 6 months, highly reactive lymphocytotoxic antibodies within 12 months prior to transplantation, and more than 2 acute rejection reactions prior to study entry. The trial requires patients and parents to give their written consent after enlightenment (informed consent).",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs ipragliflozin, placebo, and pioglitazone. The eligibility criteria for the trial include having a HbA1c value between 7.0 and 9.5%, a BMI between 20.0 and 45.0 kg/m2, and receiving pioglitazone mono-therapy for at least 4 weeks. Exclusion criteria include having type 1 diabetes mellitus, serum creatinine levels above the upper limit of normal, proteinuria, dysuria or urinary tract infection, significant renal, hepatic or cardiovascular diseases, severe gastrointestinal diseases, and being a heart failure patient.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes for related diseases. The trial involves the use of two drugs, capecitabine and hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole). The eligibility criteria for the trial include having infiltrating breast cancer with distant metastases or inoperable locally advanced disease, a positive estrogen receptor, and having experienced progressive disease during first line hormonal therapy or recurrence of disease during adjuvant hormonal therapy. The sample also includes exclusion criteria such as having other malignancies, being pregnant or breastfeeding, having contra-indications to the use of capecitabine, and having known CNS metastases.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease ankylosing spondylitis, which is associated with a list of icd-10 codes. The trial involves the use of drugs, including a placebo and golimumab, and the eligibility criteria for participants are listed in the \"criteria\" field. The inclusion criteria require a diagnosis of definite ankylosing spondylitis for at least 3 months, symptoms of active disease at screening and baseline, and no active infections. The exclusion criteria include having other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy, complete ankylosis of the spine, a history of latent or active granulomatous infection, and having had a serious infection, been hospitalized for an infection, or been treated with IV antibiotics for an infection within 2 months prior to the first administration of the study agent.",
    "The sample is a phase 3 clinical trial for postmenopausal symptoms. The trial includes the drug Brisdelle (paroxetine mesylate) and a placebo capsule. The eligibility criteria include being a female over 40 years old, experiencing moderate to severe hot flashes for at least 30 days prior to the screening visit, and meeting certain menopause criteria. Exclusion criteria include a history of self-injurious behavior, clinical diagnosis or treatment for depression, and use of an investigational study medication within 30 days prior to screening or during the study. Family of investigational-site staff are also excluded.",
    "The sample is a phase 3 clinical trial for patients with multiple sclerosis. The trial includes patients with a relapsing-remitting disease course and an expanded disability status scale (EDSS) score of 0-5.5. The trial involves the drugs fingolimod and placebo. The eligibility criteria include being between the ages of 18-55 and having a diagnosis of multiple sclerosis. Exclusion criteria include having other chronic diseases of the immune system, malignancies, acute pulmonary disease, cardiac failure, and being pregnant or nursing. Patients who discontinued study drug during the core study due to adverse events or laboratory abnormalities would be excluded from the extension phase. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) and involves the use of drugs such as indacaterol and salmeterol, as well as placebos. The trial is open to male and female adults aged 40 years or older who have signed an informed consent form. Participants must be cooperative outpatients with a smoking history of at least 20 pack years and a diagnosis of moderate to severe COPD as classified by the Global initiative for chronic obstructive lung disease (GOLD) Guidelines, 2006. They must also have a post-bronchodilator FEV1 (forced expiratory volume in one second) of less than 80% and at least 30% of the predicted normal value, as well as a post-bronchodilator FEV1/forced vital capacity (FVC) of less than 70%. Exclusion criteria include pregnancy or lactation, recent hospitalization for a COPD exacerbation, long-term oxygen therapy, respiratory tract infection, concomitant pulmonary disease, clinically significant bronchiectasis, history of asthma, diabetes, cancer, long QT syndrome, hypersensitivity to study drugs, treatment with an investigational drug, recent live attenuated vaccination, known history of non-compliance to medication, and inability to use a dry powder inhaler device or perform spirometry measurements. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 trial for the treatment of atrial fibrillation. The trial includes patients with chronic or paroxysmal non-rheumatic atrial fibrillation who have cardioembolic risk factors such as hypertension, ischemic cardiopathy, congestive heart failure, and diabetes mellitus. The trial excludes patients with clinically relevant organ disease, creatinine clearance less than 30 ml/min, gastric or duodenal ulcer, and severe anemia or polycythemia. The trial will test the effectiveness of the drugs indobufen and aspirin. The diseases are represented by a list of disease names and their corresponding ICD-10 codes are also included. The eligibility criteria are listed under inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of neurogenic urinary bladder disorder and related conditions. The trial involves the use of two different forms of propiverine hydrochloride, and the eligibility criteria includes factors such as age, consent, and specific medical conditions. The trial also has exclusion criteria, such as recent surgery or pre-existing medical contraindications for anticholinergics. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis. The trial includes patients between the ages of 40 and 80 who have been diagnosed with the disease and meet certain criteria, such as having a Forced Vital Capacity of at least 50% predicted value and being able to walk 150 meters in 6 minutes while maintaining a certain level of oxygen saturation. The trial involves the use of two drugs, pirfenidone and placebo, and has a list of exclusion criteria, such as evidence of significant obstructive lung disease or airway hyper-responsiveness, active infection, and pregnancy or lactation. The trial also has a list of primary inclusion criteria, such as no improvement in the past year and either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) being less than or equal to 90% predicted value.",
    "The sample is a phase 3 clinical trial for patients with confirmed HIV infection. The trial involves the use of two different drug combinations: darunavir/ritonavir qd + raltegravir bid and darunavir/r qd + tenofovir/emtricitabine qd (fixed dose combination). The eligibility criteria for the trial include being at least 18 years old, having a CD4 cell count of 500/mm3 or less, and having no previous treatment with antiretroviral drugs. In addition, patients must not have certain medical conditions or be taking certain medications. The trial also has non-inclusion criteria, such as being pregnant or breastfeeding, having a CD4 count over 500/mm3, or having a major IAS-USA mutation conferring resistance to one or more of reverse transcriptase or protease inhibitors on genotypic testing at screening.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of type 2 diabetes mellitus. The trial includes patients who are managed by SU and have adequate blood, liver, and kidney function. The trial excludes patients with serious cardiovascular or hepatic disease. The trial uses the drug rosiglitazone (brl49653c). The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for patients with multiple sclerosis and neuropathic pain. The trial includes patients who are willing and able to give informed consent, are 18 years or older, have been diagnosed with multiple sclerosis for at least six months, and have central neuropathic pain that is expected to remain stable for the duration of the study. Patients must also have a pain score of four or more on at least four completed Numerical Rating Scale scores in the baseline week. The trial involves the use of two drugs, placebo and Sativex, and patients must be willing to abstain from any use of cannabis during the study. Patients must also be willing to comply with all study requirements and have no significant psychiatric or medical disorders that could put them at risk or influence the study results. Exclusion criteria include a history of schizophrenia or other significant psychiatric disorders, severe non-neuropathic pain, substance abuse, severe cardiovascular disorder, epilepsy, significant renal or hepatic impairment, and pregnancy or lactation.",
    "The sample is a phase 3 clinical trial for bladder cancer. The trial includes patients with Stage Ta (any grade) transitional cell carcinoma of the bladder on the basis of cystoscopy, with recurrent disease no greater than T1, who are not at high risk for upper tract (ureter or renal pelvic) transitional cell cancers. The trial also has certain eligibility criteria for patients, such as age, performance status, life expectancy, and medical history. The trial involves the use of two drugs, cephalosporin and ciprofloxacin, and has certain restrictions on prior and concurrent therapies.",
    "The sample is a phase 3 clinical trial for postmenopausal women with bothersome hot flashes and a history of breast cancer or a refusal of estrogen replacement therapy due to perceived increased risk of breast cancer. The trial is testing the effectiveness of citalopram hydrobromide in reducing the severity of hot flashes. The trial includes eligibility criteria related to the patient's disease history, hot flash severity, and postmenopausal status. The trial also includes criteria related to the patient's prior and concurrent therapy, including restrictions on certain medications and allowance for others. The trial requires blood samples from participants and has a minimum life expectancy requirement of 6 months.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is looking at the effectiveness of the drugs bi 1356 and voglibose, as well as their respective placebos. The trial is only open to Japanese patients who have had stable antidiabetic therapy for at least 10 weeks before the trial. Patients must have a glycosylated haemoglobin A1 (HbA1c) level between 7.0 - 10.0% at the beginning of the 2-week placebo run-in phase. Patients must also be between the ages of 20 and 80, with a body mass index (BMI) of 40 kg/m2 or less. Patients who have had a myocardial infarction, stroke, or transient ischemic attack (TIA) within 6 months before the trial, have impaired hepatic function, a history of severe allergy/hypersensitivity, or have been treated with anti-diabetic or anti-obesity drugs within 3 months before the trial are excluded. Patients with a fasting blood glucose level above 240 mg/dl (=13.3 mmol/L) at Visits 2 or 3 are also excluded.",
    "This sample is for a phase 3 clinical trial for the treatment of psychosis. The trial is looking for elderly subjects who have psychosis and are willing to participate. The trial is excluding subjects who have an uncontrolled, unstable clinically significant medical condition or an established diagnosis of dementia. The drug being tested in this trial is asenapine.",
    "The sample is a clinical trial for patients with acute myelogenous leukemia in either first or subsequent complete remission. The trial is in phase 2/phase 3 and the drug being tested is decitabine. The eligibility criteria include having unfavorable risk cytogenetics, a performance status of 0-2, and adequate organ function. Patients who have received any appropriate salvage regimen before achieving complete remission may also be included. Exclusion criteria include being pregnant or lactating, having active and uncontrolled disease/infection, and having received other investigational therapy within the past 14 days.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease sarcoma and includes a list of associated icd-10 codes. The trial involves two drugs, ombrabulin (ave8062) and placebo. The eligibility criteria for the trial includes a histologically proven soft tissue sarcoma that is unresectable and has failed previous anthracycline-based and ifosfamide therapies. The exclusion criteria includes recent treatment with radiotherapy, surgery, or chemotherapy, brain metastases and carcinomatous leptomeningitis, uncontrolled hypertension, and known platinum hypersensitivity. The information provided is not exhaustive and is intended to provide an overview of the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of cancer, specifically breast cancer. The trial involves two drugs, ixabepilone and capecitabine, and the eligibility criteria for patients include having received prior treatment with both an anthracycline and a taxane, having received no more than two prior chemotherapy regimens, and not having any history of brain and/or leptomeningeal metastases. Additionally, patients may not have Grade 2 or worse neuropathy at the time of study entry and may not have had prior treatment with any epothilones and/or capecitabine. The diseases are listed as 'cancer' and 'breast cancer', and the icd-10 codes associated with these diseases are also provided.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of three drugs - exenatide, taspoglutide, and taspoglutide - in combination with metformin and/or pioglitazone or rosiglitazone. The trial has specific inclusion and exclusion criteria, such as age range, HbA1c levels, BMI, and stable weight. Patients with a history of type 1 diabetes, acute metabolic diabetic complications, clinically significant diabetic complications, proliferative diabetic retinopathy, recent myocardial infarction or stroke, abnormal clinical laboratory tests or ECG, hemoglobinopathy, or gastrointestinal disease are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the disease of hypertension. The trial involves two fixed-dose combinations of drugs, telmisartan and amlodipine, with different dosages. The eligibility criteria for the trial include a diagnosis of essential hypertension, and exclusion criteria include various medical conditions and drug dependencies. The sample includes a detailed list of exclusion criteria, such as pregnancy, breast-feeding, and clinically significant hepatic or renal impairment. The trial aims to investigate the safety and efficacy of the drug combinations in treating hypertension.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating patients with autistic disorder and behavioral symptoms using the drug aripiprazole. The eligibility criteria for the trial include having completed 8 weeks of treatment in a previous double-blind clinical trial, meeting the DSM-IV TR diagnostic criteria for AD, having a mental age of at least 18 months, and being between 6 and 17 years old. Exclusion criteria include being treatment-resistant to neuroleptic medication, having previously not responded to aripiprazole treatment, having a current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression, having had a seizure in the past year, and having a history of severe head trauma or stroke. Non-pharmacologic therapy should be stable prior to screening and consistent throughout the study.",
    "The sample is a phase 3 clinical trial for multiple sclerosis. The trial is looking at the effectiveness of the drug teriflunomide compared to a placebo. The trial is looking for participants who have a relapsing clinical course of MS and have experienced at least one relapse in the year prior to the trial or at least two relapses in the two years prior to the trial. Participants must also be clinically stable and not have had a relapse in the 60 days prior to randomization. There are exclusion criteria, such as having other major systemic diseases or being pregnant or nursing. The trial is looking to enroll participants who can comply with the study requirements and complete the trial.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus. The trial is testing the effectiveness of three drugs - ly2605541, insulin glargine, and insulin lispro - in managing blood glucose levels. The eligibility criteria include having type 2 diabetes for at least one year, having a hemoglobin A1c value between 7.0% and 12.0%, and being on a glucose-lowering regimen that includes at least one daily insulin injection. Participants must also have a BMI of 45.0 kg/m^2 or less, access to a method of communication with the site, and refrigeration in their home. They must be willing and able to adhere to a multiple daily injection regimen, inject insulin with a covered vial and syringe and prefilled pen, attend some appointments in the fasting state, and perform self blood glucose monitoring and record keeping as required by the protocol. Exclusion criteria include having received continuous subcutaneous insulin infusion therapy prior to screening, using twice daily insulin glargine prior to screening, or having excessive insulin resistance. Participants must also not be using certain medications, have certain medical conditions, or have had certain medical events within a certain timeframe.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug Seroquel SR. The trial is looking for patients who consider their current antipsychotic treatment to be inadequate due to insufficient efficacy and/or tolerability. Female patients of childbearing potential must have a negative pregnancy test and use a reliable method of birth control during the study. Patients must be able to understand and comply with the study requirements. Exclusion criteria include meeting criteria for any other diagnosis, substance abuse or dependence, risk of transmitting HIV or hepatitis B, and posing an imminent risk of suicide or danger to self or others.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves two drugs, insulin degludec and insulin glargine, and requires patients to have been diagnosed with type 2 diabetes for at least 6 months and have a maximum HbA1c level of 10%. Patients must also be currently receiving basal-oral therapy (BOT) consisting of insulin glargine once daily in combination with stable doses of metformin, insulin secretagogues, pioglitazone, sitagliptin, or alpha-glucosidase-inhibitor for at least three months prior to the trial. Patients who have used certain medications within the last three months, have cardiovascular disease, recurrent severe hypoglycemia, or are pregnant or breastfeeding are excluded from the trial. The trial also excludes patients who have previously participated in the trial or have known or suspected hypersensitivity to trial products or related products.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The trial involves the drug istradefylline (kw-6002). The eligibility criteria for the trial include completion of previous studies, non-pregnancy, and absence of certain medical conditions such as psychotic illness, variant/atypical Parkinson's disease, cancer within 5 years of enrollment, and seizure disorder. Additionally, the trial excludes individuals with high ALT/AST levels and those with neuroleptic malignant syndrome.",
    "The sample is a phase 3 clinical trial for gastroesophageal reflux disease. The trial includes patients who have a history of heartburn for at least 6 months and have experienced heartburn for at least 4 days in the week prior to the trial. The trial involves the use of drugs such as dexlansoprazole mr and placebo. The eligibility criteria include exclusion of patients with certain medical conditions such as erosive esophagitis, uncontrolled systemic disease, and Zollinger-Ellison syndrome. Patients who are pregnant or lactating, have a history of cancer within 3 years prior to screening, or have participated in a previous Dexlansoprazole study are also excluded. The trial requires patients to comply with certain requirements and is overseen by an investigator.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs ipragliflozin, placebo, and metformin. The eligibility criteria for the trial include patients who have been receiving metformin mono-therapy for at least 6 weeks, have an HbA1c value between 7.0 and 9.5%, and have a body mass index (BMI) between 20.0 and 45.0 kg/m2. The exclusion criteria include patients with type 1 diabetes mellitus, serum creatinine levels above the upper limit of normal, estimated GFR below 60ml/min/1.73m2, proteinuria (albumin/creatinine ratio > 300mg/g), dysuria and/or urinary tract infection, genital infection, significant renal, hepatic or cardiovascular diseases, and severe gastrointestinal diseases.",
    "The sample is a phase 3 clinical trial for sepsis. The trial includes patients between 12 months and less than 18 years old who are within the first 48 hours of admission to the pediatric intensive care unit (PICU) and have an endotracheal tube, central venous catheter, or Foley catheter. The trial also includes patients who are anticipated to have an indwelling arterial or central venous catheter for blood sampling during the first three days of study enrollment. The trial involves the use of metoclopramide, zinc, and selenium. The eligibility criteria include exclusion criteria such as known allergy to metoclopramide, planned removal of endotracheal tube, central venous catheter, and Foley catheters within 72 hours of study enrollment, suspected intestinal obstruction, and lack of commitment to aggressive intensive care therapies. The trial has a Data Safety Monitoring Board (DSMB) that conducts its first interim evaluation after enrollment of approximately 200 subjects, and a decision will be made by the DSMB concerning enrollment of subjects between 40 weeks gestational age and 12 months.",
    "The sample is a phase 3 clinical trial for the treatment of acromegaly, a condition characterized by excessive growth hormone production. The trial involves the use of a drug called lanreotide autogel 120 mg. The eligibility criteria for the trial include a diagnosis of acromegaly, a pituitary adenoma with a diameter of at least 10 mm, and no visual field defects. Exclusion criteria include hypersensitivity to the drug, pregnancy or lactation, and any medical conditions that may jeopardize the patient's safety or the study's objectives. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis using the drug laquinimod. The trial is open to individuals between the ages of 18 and 55 who have a confirmed diagnosis of relapsing-remitting MS and a converted Kurtzke EDSS score of 0-5.5. Participants must also meet certain inclusion criteria, such as having experienced at least one documented relapse in the 12 months prior to screening and being in a stable neurological condition. There are also exclusion criteria, such as having a known history of tuberculosis or being pregnant or breastfeeding. The trial requires participants to comply with the protocol requirements for the duration of the study.",
    "The sample is a phase 3 clinical trial for patients with hepatocellular carcinoma, a type of liver cancer. The trial involves two drugs, sorafenib and placebo, and has eligibility criteria for patients including age, life expectancy, tumor size and location, and Eastern Cooperative Oncology Group Performance Status. There are also exclusion criteria, such as previous or concurrent cancer, renal failure, cardiac disease, and active infections. The trial aims to evaluate the effectiveness of sorafenib compared to placebo in treating hepatocellular carcinoma.",
    "The sample is a phase 3 clinical trial for patients with brain edema or brain tumor. The trial is testing the effectiveness of the drugs hcrf and placebo hcrf. The eligibility criteria for the trial include a confirmed diagnosis of a primary malignant glioma, symptomatic peritumoral brain edema requiring dexamethasone treatment, and the ability to self-administer subcutaneous injections twice daily for 8 weeks or have assistance from a caregiver. Exclusion criteria include recent surgery or radiation therapy, systemic steroid use for any other indication than peritumoral brain edema, and serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine metabolic disease. The trial is also not suitable for patients with CNS infection or conditions that are considered contradictions for patients to receive niacin.",
    "The sample is a phase 3 clinical trial for HER2-negative breast cancer patients who have experienced disease progression during or after first-line treatment with Avastin and chemotherapy for locally recurrent or metastatic breast cancer. The trial involves the use of bevacizumab (Avastin) and chemotherapy as treatment options. The eligibility criteria include being a female patient over 18 years of age, having confirmed HER2-negative breast cancer, and having an ECOG performance status of 0-2. The exclusion criteria include having active malignancy other than superficial basal cell and superficial squamous cell carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5 years, inadequate renal function, clinically relevant cardio-vascular disease, known CNS disease except for treated brain metastases, chronic daily treatment with high-dose aspirin or clopidogrel, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial involves the use of two drugs, paroxetine and lithium. The eligibility criteria for participants include being over 18 years old, having a DSM-IV diagnosis of major depression, and having a positive family history of bipolar disorder or completed suicide. Exclusion criteria include not being able to give informed consent, being pregnant or breastfeeding, having additional psychiatric diagnoses such as PTSD or psychosis, having a history of mania or hypomania, and having a current or prior adequate trial of lithium or paroxetine. Participants must also not have a current depressive episode less than 4 weeks or greater than 12 months in duration, and must not have active substance abuse or dependence in the last 6 months. Additionally, participants must not be currently using other medications such as antidepressants for the treatment of depression, and must not have any clinically significant medical illness, particularly kidney problems.",
    "The sample is a phase 3 clinical trial for diabetic macular edema. The trial includes patients with type 1 or type 2 diabetes mellitus and visual acuity impairment. The trial involves the use of ranibizumab and a sham drug. The eligibility criteria include stable medication for diabetes treatment for the last 3 months, while exclusion criteria include uncontrolled systemic or ocular diseases, recent laser photocoagulation or intraocular surgery, and high blood pressure. The extension inclusion criteria require completion of the core study.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The eligibility criteria include having histologically determined adenocarcinoma or adenosquamous carcinoma, advanced unresectable pancreatic cancer, and no previous treatment for pancreatic cancer except resection. Patients must also have an ECOG Performance Status of 0 or 1, be between the ages of 20 and 79, and have sufficient function of major organs. Exclusion criteria include pulmonary fibrosis or interstitial pneumonia, watery diarrhea, active infections, serious complications, and metastasis in the CNS. Pregnant or nursing females, males attempting to produce a pregnancy, and patients with severe mental disorders are also excluded. The trial will test the effectiveness of gemcitabine plus ts-1, ts-1, and gemcitabine as treatments for pancreatic cancer.",
    "The sample is for a phase 3 clinical trial for psoriasis. The trial involves the drug etanercept and the eligibility criteria includes both male and female participants between the ages of 18 and 70. Healthy volunteers are excluded from the trial. The diseases are listed as psoriasis and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C virus. The trial includes patients who have previously failed treatment with peginterferon alfa and ribavirin, or are intolerant or ineligible to P/R due to neutropenia, anemia, depression or thrombocytopenia with fibrosis/cirrhosis, or are treatment naive. The trial also includes patients with HCV RNA levels of at least 10,000 IU/mL and who are seronegative for HIV and Hepatitis B surface antigen. The trial permits subjects with compensated cirrhosis, but excludes those with prior treatment of HCV with HCV direct acting antiviral (DAA), evidence of a medical condition contributing to chronic liver disease other than HCV, evidence of decompensated liver disease, diagnosed or suspected hepatocellular carcinoma or other malignancies, uncontrolled diabetes or hypertension. The trial uses a combination of drugs including asunaprevir (asv), daclatasvir (dcv), pegylated-interferon alfa 2a (pegifn), and ribavirin (rbv).",
    "The sample is a phase 3 clinical trial for depression and related disorders, with a focus on postmenopausal women between the ages of 40 and 70. The trial involves the use of two drugs, desvenlafaxine succinate sustained-release and escitalopram, and includes a list of inclusion and exclusion criteria for participants. The diseases being studied include depression, depressive disorder, and major depressive disorder, with corresponding ICD-10 codes provided. The eligibility criteria include a primary diagnosis of MDD without psychotic features, a MADRS total score of 22 or higher, and the absence of certain medical conditions or substance abuse.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorders. The trial involves the use of drugs such as olanzapine, amantadine, metformin, and zonisamide. The eligibility criteria for the trial include having a diagnosis of schizophrenia or schizoaffective disorder, being able to visit the doctor's office regularly, and not having certain medical conditions or allergies. The trial also has exclusion criteria, which include having certain medical conditions or a history of Parkinson's Disease.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe atopic dermatitis using tacrolimus ointment. The trial is open to both male and female patients of any ethnic group who are known to be responsive to topical steroids. Patients must have a Rajka/Langeland score of at least 4.5 and must not have any genetic epidermal barrier defects such as Netherton's syndrome or generalised erythroderma. Patients must also not be pregnant or breastfeeding, have a skin infection on the affected area, or have a known hypersensitivity to macrolides in general, to tacrolimus or any excipient of the ointment. Patients must not be simultaneously participating in any other drug trial or have less than 28 days pass between the end of the previous trial and this one. Patients must not have any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the communication with the investigator. Female patients of childbearing potential must agree to maintain adequate birth control practice during the trial period and during the first four weeks after the end of the study. Patients must not have taken and agree not to take for the complete study period any medication or therapy prohibited by the protocol.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of thyroid cancer using the drug zd6474 (vandetanib). The trial is looking for patients with unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer who have measurable tumors and are able to swallow medication. The record includes the inclusion and exclusion criteria for the trial, such as recent major surgery or radiation therapy, brain metastases or spinal cord compression, significant cardiac events, and previous treatment with ZD6474. The record also includes the list of disease names and icd-10 codes associated with the trial.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm. The trial involves the use of the drugs prednisone and thalidomide. The eligibility criteria for the trial include having histologically confirmed multiple myeloma, detectable serum M-component or urinary excretion of light chain protein, and having previously undergone autologous stem cell transplantation. Patients must also meet certain age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other criteria. Patients must not have any other major medical illness or condition that would preclude study participation and must not be pregnant or nursing. The trial does not allow for concurrent anti-cancer therapy or investigational therapy.",
    "This sample is from a clinical trial in phase 3 and focuses on sleep initiation and maintenance disorders. The trial includes the use of drugs such as zolpidem-mr (modified release), zolpidem (sl800750), and a placebo. The eligibility criteria for the trial require a diagnosis of primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.",
    "The sample is a phase 3 clinical trial for recurrent ovarian epithelial cancer after first line chemotherapy. The trial requires patients to have received at least 4 courses of either cisplatin or carboplatin, with at least 12 months since the prior chemotherapy. Patients must have measurable disease by clinical exam or diagnostic laparoscopy, with at least one lesion greater than 1 cm in diameter. Patients must also meet certain patient characteristics, such as being 18 years or older, having a WHO performance status of 0-2, and meeting certain hematopoietic, hepatic, and renal criteria. The trial excludes patients with leptomeningeal or brain metastases, peripheral neurotoxicity greater than grade 2, complete bowel obstruction, or other malignancies except adequately treated basal cell skin cancer or carcinoma in situ of the cervix. The trial allows for no more than 1 prior regimen of chemotherapy and does not specify biologic or endocrine therapy or radiotherapy.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who have signed informed consent for a translational study and have an available FFPE tumor sample for miR-31-3p and miR-31-5p expression testing. The trial involves the use of cetuximab and folfox drugs. The eligibility criteria include being a part of the PETACC08 study and the exclusion criteria include patients who have withdrawn their consent for the PETACC08 and/or translational study. The diseases are listed as 'colorectal cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial is looking at the effectiveness of oxymorphone extended release as a treatment for moderate to severe chronic non-neuropathic lower back pain that has been present daily for at least several hours per day for a minimum of three months prior to the screening. The trial is looking for opioid-naive males or females who are at least 18 years old and in good health as determined by the investigator on the basis of medical history and physical examination. The trial has a list of inclusion and exclusion criteria that the participants must meet. The inclusion criteria include having an initial pain intensity score of at least 50 mm VAS and not having any nerve/plexus blocks within 4 weeks of screening. The exclusion criteria include being pregnant and/or lactating, having radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia, or having a history of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of reflux esophagitis and includes a list of ICD-10 codes associated with the disease. The trial involves the use of drugs such as esomeprazole and omeprazole. The eligibility criteria for the trial include patients with healed reflux esophagitis verified by EGD in a previous study and patients receiving general treatment with PPI. The exclusion criteria include patients with gastric or duodenal ulcer verified by EGD within 12 weeks before randomization and patients who have used any PPI from 14 days before EGD performed at the screening visit to the day of randomization.",
    "The sample is a phase 3 clinical trial for patients with myocardial infarction. The trial involves the use of two drugs, bivalirudin and unfractionated heparin. The eligibility criteria for the trial include having clinical symptoms consistent with AMI, ST-segment elevation, and agreeing to the study protocol. Exclusion criteria include known hypersensitivity or contraindication to certain medications, prior administration of certain therapies, current use of coumadin, and various medical conditions. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period, and those who underwent coronary stent implantation within the past 30 days are also excluded.",
    "The sample is a record of a clinical trial in phase 3, focused on chronic kidney disease stage 5. The trial involves the use of two drugs, fosrenol (lanthanum carbonate) and sevelamer hydrochloride. The eligibility criteria for the trial include being an adult with end-stage renal disease who is receiving dialysis. However, there are also exclusion criteria, such as having significant gastrointestinal disorders, being pregnant or nursing, currently taking certain medications, being HIV positive, or having clinically significant liver disease.",
    "The sample is a phase 3 clinical trial for the treatment of depression in patients with bipolar I disorder. The trial includes patients who have had at least one previous manic or mixed episode and are currently experiencing a major depressive episode. The patients must have had no more than 6 mood episodes in the last year and must be taking one or two of the allowed mood stabilizers. The trial requires written informed consent and patients must be between 18 and 65 years old and in good health, except for their bipolar I disorder. Women of childbearing potential must use contraception during the study and for 30 days after participation. The trial has inclusion and exclusion criteria, including exclusion of patients with other Axis I disorders, psychotic symptoms, active suicidal ideation, eating disorders, substance abuse or dependence, and other medical conditions. The trial also excludes patients who have previously used armodafinil or participated in a clinical study with armodafinil. The trial does not allow patients who have been treated with VNS, DBS, ECT, or rTMS within 3 months of the screening visit. Pregnant or lactating women are also excluded from the trial.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on Parkinson's disease. The icd-10 code for Parkinson's disease is 'G20'. The drug being tested is ropinirole. The eligibility criteria for the trial include having idiopathic Parkinson's disease, being in Modified Hoehn and Yahr Scale Stages II - IV, having a stable dose of L-dopa for at least 4 weeks prior to screening, and lack of control with L-dopa therapy. Women of child-bearing potential must use a clinically accepted form of birth control. The exclusion criteria include having significant and/or uncontrolled medical conditions (excluding Parkinson's disease) within 3 months of screening, having any abnormality at screening that is considered clinically relevant by the Investigator, having dementia, using dopamine agonists within 4 weeks of screening visit, and participating in other investigational drug studies.",
    "The sample is a phase 3 clinical trial for patients aged 18 or older with cancer pain or non-cancer pain such as chronic low back pain or osteoarthritis. The trial is testing the efficacy of oxycodone naloxone and oxycodone pr tablets for patients who are currently receiving a WHO step II or III opioid and require the initiation of a WHO step III opioid or are currently receiving a WHO step III opioid. Patients must also have opioid-related constipation and meet certain eligibility criteria. The trial has exclusion criteria such as pregnancy or breastfeeding, known contraindication or hypersensitivity to the study medication, and clinically significant impairment of cardiovascular, respiratory, liver or kidney function disease. Patients who have participated in a clinical research involving a new chemical entity or an experimental drug within 30 days of study entry are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of painful diabetic peripheral neuropathy. The trial involves the use of the drugs pregabalin and placebo. The eligibility criteria for the trial include having type 1 or 2 diabetes with painful neuropathy, currently being treated with one NSAID for a co-morbid pain condition, and meeting a pre-defined level of pain severity at entrance. The exclusion criteria include having a history of failed pregabalin treatment, participating in a previous or ongoing pregabalin clinical trial, and having neurologic disorders unrelated to diabetic neuropathy that may confound the assessment of distal neuropathic pain. The diseases are listed as 'painful diabetic peripheral neuropathy' and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for early rheumatoid arthritis. The trial is testing the effectiveness of methotrexate and a methotrexate placebo. The eligibility criteria for the trial includes being 18 years or older, having a recent stable medical history, and a diagnosis of rheumatoid arthritis with a disease duration of less than 3 years. The patient must have at least 8 swollen joints out of 66 assessed, at least 10 tender joints out of 68 assessed, at least 1 joint erosion or rheumatoid factor positivity, and an erythrocyte sedimentation rate of at least 28 mm/1h or a C-reactive protein of at least 1.5 mg/dl. Patients who have chronic arthritis diagnosed before the age of 16, have received certain previous treatments, are permanently wheelchair-bound or bedridden, or are considered unsuitable candidates by the investigator are excluded from the trial. Female patients who are pregnant, breastfeeding, or considering becoming pregnant are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have been diagnosed with T2DM and have been on stable oral anti-diabetic therapy for at least 12 weeks prior to the screening visit. The trial also has specific inclusion and exclusion criteria, such as age, HbA1c levels, and BMI. Patients with acute metabolic diabetes complications or a history of certain medical events are excluded from the trial. The trial involves the use of two drugs, vildagliptin and placebo. The sample includes the eligibility criteria for the trial, including the specific requirements for inclusion and exclusion.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and mania. The trial involves the drugs cariprazine and placebo. The eligibility criteria include patients who have provided informed consent, currently meet the DSM-IV-TR criteria for bipolar I disorder, are voluntarily hospitalized for a current manic episode, and have normal physical examination, laboratory, vital signs, and/or ECG. Patients with a diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months are excluded from the trial.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B. The trial is looking for patients who have a documented history of chronic hepatitis B, with detectable serum Hepatitis B Surface Antigen (HBsAg) and HBeAg-positive at the screening visit. The trial also requires patients to have a history of evidence of chronic liver inflammation, elevated serum Alanine aminotransferase (ALT) level, and serum HBV DNA level \u2265 6 log10 copies/mL. Patients must also have chronic liver inflammation on previous liver biopsy within the previous 24 months. The trial excludes patients who have co-infection with Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), or Human Immunodeficiency Virus (HIV), and those who have received certain drug therapies or have medical conditions that require prolonged or frequent use of certain drugs. Patients with a history of hepatic decompensation, malignancy of any organ system, or clinical and laboratory evidence of chronic pancreatitis are also excluded. Patients who are pregnant or breastfeeding, or women of child-bearing potential who are unwilling to practice birth control are also excluded.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with essential hypertension and a 24-hour mean systolic blood pressure between 140 mm Hg and 180 mm Hg. The trial drugs are azilsartan medoxomil and amlodipine, and the eligibility criteria include having clinical laboratory evaluations within the reference range, being willing to discontinue current antihypertensive medications, and not having any exclusion criteria such as recent history of myocardial infarction, heart failure, or drug abuse. The trial also includes exclusion criteria such as having severe renal dysfunction or disease, being non-compliant with study medication during placebo run-in period, or having any other serious disease or condition that would compromise subject safety.",
    "The sample is a phase 3 clinical trial for hypertension patients. The trial includes three drugs: placebo, valsartan, and fimasartan. The eligibility criteria for the trial include being between the ages of 20 and 75, having essential hypertension with a sitting diastolic blood pressure between 90mmHg and 110mmHg at baseline, and being able to understand and cooperate with the trial. Exclusion criteria include severe hypertension, orthostatic hypotension, secondary hypertension, abnormal renal or liver function, severe heart disease, and a history of alcohol or drug abuse within the past 2 years. The trial also excludes childbearing and breastfeeding women and those with a possibility of pregnancy who do not prevent conception with acknowledged methods.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes associated with the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on idiopathic restless legs syndrome. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (spm 962 and a placebo of spm 962). The eligibility criteria for participants are also listed, including requirements such as meeting specific diagnostic criteria for restless legs syndrome, having a certain score on a symptom assessment, and not having certain medical conditions or taking certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of rheumatoid arthritis. The trial is testing the effectiveness of the drug fostamatinib compared to a placebo. The trial is looking for participants who have been diagnosed with active rheumatoid arthritis, are currently taking methotrexate, and have at least 6 swollen and 6 tender/painful joints. Participants must also meet at least one of the following criteria: a positive rheumatoid factor, radiographic erosion within the past 12 months, or the presence of serum anti-cyclic citrullinated peptide antibodies. Exclusion criteria include pregnancy or breastfeeding, poorly controlled hypertension, liver disease, certain inflammatory conditions, recent or significant cardiovascular disease, significant active or recent infection, previous failure to respond to certain treatments, severe renal impairment, and neutropenia.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the drugs saxagliptin and placebo. The eligibility criteria for the trial include being diagnosed with type 2 diabetes, having a documented history of CrCl <50 ml/min within the 3 months prior to enrollment, and having an HbA1c level between 7.0% and 11.0%. The exclusion criteria include having type 1 diabetes, a history of diabetic ketoacidosis or hyposmolar non-ketonic coma, and previous or current treatment with any DPP-IV inhibitor and/or GLP-1 mimetic. The diseases are listed as 'type 2 diabetes' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension. The trial is testing the effectiveness of oral treprostinil (ut-15c) sustained release tablets compared to a placebo. The trial is looking for participants between the ages of 12 and 70 who weigh at least 45 kg and have PAH that is either idiopathic/heritable, associated with repaired congenital systemic-to-pulmonary shunts, associated with collagen vascular disease, or associated with HIV. Participants must also have a baseline 6-minute walk distance between 150 and 450 meters and be currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days. Exclusion criteria include nursing or pregnancy, receiving a prostacyclin within the past 30 days, PAH due to conditions other than those listed in the inclusion criteria, history of uncontrolled sleep apnea, renal insufficiency, anemia, left-sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease, and use of an investigational drug within 30 days of baseline.",
    "The sample is a phase 3 clinical trial for patients with metastatic or unresectable colorectal cancer. The trial involves the use of a combination of drugs including fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. Patients must meet certain eligibility criteria, including having histologically confirmed colorectal adenocarcinoma, measurable disease, and an ECOG performance status of 0-2. They must also meet certain patient characteristics, such as having a life expectancy of more than 3 months and no prior or concurrent CNS metastasis. Prior concurrent therapy is also taken into consideration, with certain treatments being excluded.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) patients. The trial includes male and female adults over 40 years old with a smoking history of at least 20 pack years and a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2005. The trial also requires patients to have a post-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% and at least 30% of the predicted normal value, as well as a post-bronchodilator FEV1/FVC (forced volume capacity) of less than 70%. Patients with certain exclusion criteria, such as recent hospitalization for a COPD exacerbation or a history of lung cancer, are not eligible for the trial. The trial will test the effectiveness of drugs such as indacaterol and formoterol, as well as placebos. The eligibility criteria for the trial are further defined in the \"criteria\" column of the table.",
    "The sample is a record of a clinical trial with a phase 3 designation and the disease being studied is prostate cancer. The icd-10 codes associated with the disease are listed as \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being tested are degarelix and goserelin acetate. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include giving written consent, completing a previous trial, and not having been withdrawn from a previous trial.",
    "The sample is a record of a clinical trial for the treatment of glaucoma. The trial is in phase 2/phase 3 and the disease being studied is glaucoma. The icd-10 codes associated with the disease are listed. The drugs being tested are ranibizumab and mitomycin (mmc). The eligibility criteria for the trial are listed, including age, previous surgeries, and current infections or inflammation. The sample also includes exclusion criteria, such as being enrolled in another investigational study or having an abnormality preventing reliable applanation tonometry in each eye.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial is looking for subjects between the ages of 16 and 75 who have well-characterized focal epilepsy or epileptic syndrome and experience at least 2 but no more than 40 partial onset seizures per 4 weeks during the 8-week baseline period. The subjects must be on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED \u2264 50 % of the minimum recommended maintenance dose. The trial is excluding subjects with seizure type IA non-motor as their only seizure type, a history or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline, and other serious uncontrolled diseases. The drugs being tested in the trial are brivaracetam.",
    "The sample is a phase 3 clinical trial for the treatment of vomiting and nausea caused by chemotherapy. The trial includes patients with solid malignant tumors who are scheduled to receive their first course of an anthracycline and cyclophosphamide containing moderately emetogenic chemotherapy regimen. The trial involves the use of several drugs, including casopitant (gw679769) oral tablets, casopitant (gw679769) intravenous, dexamethasone intravenous, ondansetron oral tablets, and placebo. The eligibility criteria for the trial include being at least 18 years old, having an ECOG performance status of 0, 1, or 2, and meeting certain hematologic and metabolic criteria. Women of childbearing potential must commit to consistent and correct use of an acceptable method of birth control. The exclusion criteria include having previously received cytotoxic chemotherapy, being pregnant or lactating, and having a known hypersensitivity or contraindication to certain drugs.",
    "The sample is a phase 3 clinical trial for smoking cessation. The trial includes participants with stable cardiovascular disease and who smoke more than 10 cigarettes per day. The trial involves the use of two drugs, placebo and varenicline. The eligibility criteria include having a documented cardiovascular disease and exclusion criteria include unstable cardiovascular disease, cardiovascular events in the past 2 months, and moderate or severe chronic obstructive pulmonary disease (COPD).",
    "The sample is a record of a clinical trial in phase 3 for the treatment of ovarian cancer. The trial involves the drugs trabectedin, doxil, and dexamethasone. The eligibility criteria for the trial include having histologically proven epithelial ovarian cancer, having received only one platinum-based chemotherapy regimen, having an Eastern Cooperative Oncology Group status of not more than 2, and having experienced progression more than 6 months after the start of initial chemotherapy treatment. The exclusion criteria include having received more than one prior chemotherapy regimen, experiencing progression within 6 months after starting initial chemotherapy, having prior exposure to anthracyclines, being unwilling or unable to have a central venous catheter, and having known clinically relevant central nervous system metastasis.",
    "The sample is a phase 3 clinical trial for patients suffering from peripheral neuropathy and pain that is not fully relieved by their current therapy. The trial is testing the effectiveness of the drugs Sativex and placebo. The eligibility criteria include being 18 years or older, having been diagnosed with PNP for at least six months, and having mechanical allodynia within the affected nerve(s). The trial also requires stable doses of regular pain medication and non-pharmacological therapies for at least 14 days prior to the screening visit. Exclusion criteria include having concomitant pain that may interfere with the assessment of PNP, using cannabis or cannabis-based medications within the last year, and having a history of alcohol or substance abuse. The trial also excludes patients with certain medical conditions such as CRPS type 1, cancer-related neuropathic pain, and neuropathic pain resulting from diabetes mellitus.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes using the drug candesartan cilexetil. The trial includes patients who were diagnosed with type 1 diabetes before the age of 36 and require continuous insulin treatment within 1 year of diagnosis. Patients must have had stable diabetic therapy within the last 6 months and have a resting mean sitting SBP < 130 mmHg and mean sitting DBP < 85 mmHg with retinal photograph grading level 10/10. Patients with certain conditions, such as cataract or media opacity, angle closure glaucoma, or history of retinopathy, are excluded from the study. Pregnant or lactating women or women of childbearing potential not practicing an adequate method of contraception are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis B virus in pediatric patients. The trial includes patients who are hepatitis B surface antigen-positive and have detectable hepatitis B e antigen, but no detectable anti-HBe antibodies. The trial also requires patients to have a certain level of alanine aminotransferase and evidence of the presence of hepatitis B virus DNA. The trial will test the effectiveness of the drug entecavir compared to a placebo. The eligibility criteria includes age, prior therapy, and co-infection with other viruses. The trial excludes patients with decompensated liver disease, liver transplant recipients, and other conditions that may cause increased ALT levels.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients with a diagnosis of schizophrenia and a CGI-S score of 4 or less at baseline. The trial excludes patients who are currently receiving antipsychotic treatment, or have received antidepressants or mood stabilizers within 2 weeks of randomization, or have experienced an acute exacerbation of schizophrenia within 3 months of baseline. The trial will test the effectiveness of ziprasidone and risperidone as potential treatments for schizophrenia. The diseases are listed as 'schizophrenia' and the corresponding ICD-10 codes are listed as well.",
    "The sample is a clinical trial for metastatic colorectal cancer patients in phase 2/phase 3. The trial involves the use of three drugs, mitomycin c, capecitabine, and bevacizumab. The eligibility criteria include having a histological diagnosis of colorectal cancer, having metastatic disease that is not resectable, being over 18 years old, having measurable and/or non-measurable disease as assessed by CT scan, and having an ECOG performance status of 0, 1, or 2. Patients must also meet certain requirements for bone marrow, renal, and hepatic function, and have a life expectancy of at least 12 weeks. Exclusion criteria include having certain medical or psychiatric conditions, uncontrolled hypertension, active bleeding disorders, and recent major surgical procedures. Women and partners of women of childbearing potential must agree to use adequate contraception, and written informed consent is required.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves patients who are at least 12 years old and have a pre-bronchodilator FEV1 of 40-90% predicted. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are listed, including requirements for current asthma therapy and exclusion criteria such as a history of life-threatening asthma or allergies to study drugs. The sample also includes a list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs exenatide and placebo. The eligibility criteria for the trial include having a stable dose of metformin or a combination of metformin and sulfonylurea for at least 3 months prior to screening, having an HbA1c level between 7.1% and 11.0%, having a BMI between 21 kg/m^2 and 35 kg/m^2. The exclusion criteria include having previously participated in the study or any other study using exenatide or GLP-1 analogs, having participated in any interventional, medical, surgical, or pharmaceutical study within 30 days of screening, having characteristics that contraindicate metformin or sulfonylurea use, having been treated with exogenous insulin for more than 1 week within the 3 months prior to screening, and having used drugs for weight loss within 1 month of screening.",
    "This sample is from a clinical trial in phase 3 for Parkinson's disease. The trial is testing the drug rotigotine on patients with early and advanced idiopathic Parkinson's disease who experience early morning motor impairment. The inclusion criteria for the trial is having Parkinson's disease with early morning motor impairment, while the exclusion criteria is having atypical Parkinsonian syndromes. The icd-10 code for Parkinson's disease is G20.",
    "The sample is a phase 3 clinical trial for multiple myeloma, a type of blood cancer. The trial includes patients with different stages of the disease, including refractory and smoldering myeloma. The trial involves the use of two drugs, lenalidomide and melphalan. The eligibility criteria for the trial include having active multiple myeloma requiring treatment, having stable disease or being responsive to at least 2 months of any induction therapy, and having no more than 12 months of any prior therapy. Patients must also meet certain medical criteria, such as having a certain level of peripheral blood stem cells and a certain level of lung function. Additionally, patients must not have certain medical conditions, such as uncontrolled diabetes or an active serious infection, and must not be pregnant or nursing. Women of childbearing potential must have a negative pregnancy test and use two forms of birth control while taking lenalidomide.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial is testing the effectiveness of the drug Seroquel (quetiapine) on stable schizophrenic patients between the ages of 18 and 65. The inclusion criteria for the trial include patients who have provided written informed consent and remain clinically stable after switching to a stable dose of Seroquel. The exclusion criteria include patients with a risk of suicide, other disorders or substance abuse that might interfere with the patient's ability to co-operate, expected non-compliance to treatment, known diabetes mellitus, contraindications, intolerance or non-responsiveness to Seroquel or other safety issues. The diseases column lists only one disease, which is schizophrenia, and the icdcodes column lists the corresponding ICD-10 codes for the disease.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial involves the use of multiple drugs, including olodaterol and tiotropium, and requires patients to meet certain eligibility criteria, such as being 40 years of age or older, having a 10 pack year smoking history, and being able to perform pulmonary function tests. Patients with significant other diseases or abnormal hematology, chemistry, or urinalysis are excluded from the trial, as are those with a history of asthma, thyrotoxicosis, or paroxysmal tachycardia related to beta agonists. Other exclusion criteria include a history of heart failure or pulmonary resection, taking certain medications, and being enrolled in another study or rehabilitation program. Pregnant or nursing women and those who are not willing to comply with pulmonary medication washouts are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of primary insomnia. The trial involves the use of the drugs suvorexant and a dose-matched placebo to suvorexant. The eligibility criteria for participants include a diagnosis of primary insomnia, ability to read and complete questionnaires, agreement to use contraception if female, and a minimum score on the Mini Mental State Examination if over 65 years old. Exclusion criteria include pregnancy, recent or active neurological disorders, unstable cardiovascular disorders, history of bipolar disorder or substance abuse, and evidence of suicidality. Additionally, participants must not have traveled across more than 3 time zones or worked permanent night shifts or rotating day/night shifts in the past 2 weeks, and must have a BMI of less than or equal to 40 kg/m^2.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients with histologically proven invasive adenocarcinoma with at least one axillary lymph node showing evidence of tumor among a minimum of six resected lymph nodes. The definitive surgical treatment must be either mastectomy or breast conserving surgery with axillary lymph node dissection for operable breast cancer. The trial excludes patients who have received prior systemic anticancer therapy for breast cancer, immunotherapy, hormonotherapy, or chemotherapy. Additionally, patients who have received prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy are also excluded. The trial will test the efficacy of docetaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide as treatment options.",
    "The sample is a phase 3 clinical trial for children between the ages of 12 and 24 months who suffer from symptoms of Atopic Dermatitis (AD) lasting cumulatively for at least 2 months since birth. The trial involves the use of a placebo and levocetirizine as drugs. The eligibility criteria include a Modified Severity Scoring of Atopic Dermatitis (SCORAD) Index of at least 10, and a biological family history of atopy (AD, allergic rhinitis or asthma). The trial also has exclusion criteria, such as having chronic pulmonary diseases, being treated with immunomodulator medication, or having received allergen-specific immunotherapy. The trial requires a wash-out period for certain medications, and prohibits the intake of any prohibited medication during the selection period.",
    "The sample is a phase 3 clinical trial for the treatment of melanoma, a type of skin cancer. The trial is looking at the effectiveness of two drugs, temozolomide and dacarbazine. The eligibility criteria for participants include being 18 years or older, having stage IV melanoma that is not curable by surgery, having a good performance status, meeting certain laboratory requirements, being able to take oral medication, and having been disease-free from cancer for at least 5 years (with some exceptions). Participants must also provide written informed consent and have recovered from any major surgery or adjuvant treatment. Exclusion criteria include having ocular melanomas, brain metastases, having received prior cytokine or chemotherapy for stage IV disease, and being pregnant or nursing.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial includes child and adolescent patients between the ages of 6 and 16 who have been newly diagnosed with ADHD within the past 3 months. The patients must meet the DSM-IV-TR diagnostic criteria for ADHD and have an ADHDRS-IV-Parent:Inv score at least 1.5 standard deviations above the age norm for their diagnostic subtype at both Visit 1 and Visit 2. In addition, they must have a CGI-ADHD-S score of 4 at both visits. The trial will test the efficacy of atomoxetine hydrochloride compared to a placebo. Patients with a history of ADHD diagnosis longer than 3 months prior to Visit 1 and those who weigh less than 20 kg at study entry are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying atrial fibrillation and cardiovascular disease. The drugs being tested are irbesartan and a placebo. The eligibility criteria include having a systolic blood pressure of at least 110 mmHg, not currently taking an angiotensin receptor blocking agent, and not having any previous intolerance to such agents. There are also exclusion criteria, such as having a requirement for clopidogrel or oral anticoagulant, documented peptic ulcer disease within the previous 6 months, or ongoing alcohol abuse.",
    "The sample is a phase 3 clinical trial for patients with acute coronary syndromes. The trial includes patients who have non-ST-segment elevation with elevated troponin and are scheduled for coronary angiography/PCI within 2-24 hours from the time of planned randomization. Patients must be eligible for treatment with prasugrel, aspirin (ASA), and a glycoprotein IIb/IIIa receptor (GPIIb/IIIa) inhibitor as per respective labels. They may also be on a maintenance dose of clopidogrel 75 mg and must be able to switch to prasugrel. Patients must be enrolled at a cardiac catheterization laboratory hospital or at a hospital/ambulance service affiliated with a cardiac catheterization laboratory hospital. Exclusion criteria include patients with ST-segment elevation myocardial infarction (STEMI), cardiogenic shock, refractory ventricular arrhythmias, New York Heart Association (NYHA) Class IV congestive heart failure (CHF), or those who had cardiac arrest within 1 week of entry or randomization into the study.",
    "The sample is a phase 3 clinical trial that involves patients with various advanced solid tumors, including metastatic pancreatic cancer, bone metastases, and endocrine cancer. The trial is testing the effectiveness of a drug called amg 479 in combination with gemcitabine compared to a placebo. The eligibility criteria for the trial include having untreated metastatic adenocarcinoma of the pancreas, adequate hematologic, renal, and liver function, and an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. Patients who have had prior chemotherapy or radiotherapy for pancreatic cancer, central nervous system metastases, or an external biliary drain are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of familial hypercholesterolemia. The trial includes male and female children and adolescents aged 10-17 years who have heterozygous familial hypercholesterolemia. The trial involves the use of two drugs, rosuvastatin and placebo. The eligibility criteria for the trial include certain medical conditions and lab test results, a history of reaction to rosuvastatin or other statin drugs, and the use of specified disallowed medications.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of chronic primary insomnia. The trial involves the use of two drugs, esmirtazapine and placebo, and includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial are also listed, including both inclusion and exclusion criteria. In order to be included in the trial, participants must have a documented diagnosis of chronic primary insomnia, while exclusion criteria include other sleep disorders, significant medical or psychiatric illness, substance abuse, and a history of bipolar disorder or family history of suicide, among others.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who meet DSM-IV criteria for schizophrenia and are between the ages of 18 and 75. The trial involves the use of drugs such as sm-13496 (lurasidone hcl), placebo, and risperidone. The eligibility criteria include exclusion of patients with a history of neuroleptic malignant syndrome, water intoxication, paralytic ileus, Parkinson's disease, or malignancy. Patients must provide written informed consent to participate in the study.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes three drugs: ta-7284 low, ta-7284 high, and placebo. The eligibility criteria for the trial include being diagnosed with type 2 diabetes mellitus at least 3 months before the run-in period, having an HbA1c level between 7.0% and 10.0%, and being at least 20 years old. Exclusion criteria include having type 1 diabetes mellitus, severe diabetic complications, fasting plasma glucose levels above 270 mg/dL, a history of hereditary glucose-galactose malabsorption or primary renal glucosuria, or requiring insulin therapy.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have been diagnosed with schizophrenia (paranoid, disorganized or undifferentiated type) according to the Diagnostic and Statistical Manual - Fourth Edition (DSM-IV). The trial also requires patients to have a score of at least 4 on at least two of a subset of selected PANSS items and a total score on these five items of at least 17, as well as a score of at least 5 on the CGI-S (clinical global impression - severity). Patients must have a body weight of at least 60kg and be willing to be hospitalized for 9 days initially. Exclusion criteria include a primary active mental illness diagnosis other than schizophrenia, psychotic symptoms that can be explained by substance intake or medical illness, pregnancy, breast-feeding, or planning to become pregnant, a history of treatment resistance, and unstable or significant medical illness that would increase risk of taking study medication or would confuse the interpretation of the study. The trial will test the efficacy of paliperidone er tablets, quetiapine tablets, and placebo - all over encapsulated.",
    "The sample is a record of a clinical trial in phase 3, focused on kidney transplant. The icd-10 codes associated with the disease are listed, along with the drug being tested, which is sirolimus. The eligibility criteria for the trial are also provided, including inclusion criteria such as being a first-time kidney transplant recipient and having a weight over 88 pounds, and exclusion criteria such as having very high cholesterol levels or being obese. Additionally, the trial excludes organ donors over a certain age.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial involves patients who have completed a screening protocol within the past six months and have taken a certain amount of immediate-release or sustained-release methylphenidate or have completed a previous protocol. The patients must agree to only take the supplied study drug during the four-week treatment phase and must be able to comply with the study visit schedule. The trial also requires the participation of the patient's parent(s) and teacher. Patients with certain gastrointestinal problems, glaucoma, seizure disorder, psychotic disorder, clinical depression, Tourette's syndrome, allergy to methylphenidate, or high blood pressure are excluded from the trial. Female patients who have begun menstruation are also excluded.",
    "The sample is a phase 3 trial for asthma. The eligibility criteria include being an outpatient over 12 years old with a diagnosis of asthma, having a certain level of lung function, and demonstrating reversibility of lung function with a specific medication. Participants must also not have certain medical conditions or take certain medications. Exclusion criteria include recent hospitalization for asthma, certain respiratory conditions, and allergies to certain medications. Participants must also not be smokers or have a smoking history, and cannot be immediate family members of the study staff.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus and cardiovascular disease who have inadequate glycaemic control. The trial involves the drugs dapagliflozin and placebo. The eligibility criteria for inclusion in the trial include having uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment, while exclusion criteria include having type 1 diabetes or diabetes insipidus, taking 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or having poorly controlled diabetes, and having any clinically significant illness that would compromise the patient's safety and participation in the study. The icd-10 codes for the diseases are also provided.",
    "The sample is for a phase 3 clinical trial for type 2 diabetes. The trial includes men and women between the ages of 30 and 75 years who have been diagnosed with type 2 diabetes for no more than 7 years and are negative for anti-GAD antibodies. Participants must be on 0-2 oral anti-diabetic medications and have an A1c level between 5.5% and 9.0% if on oral anti-diabetic medications, or between 6.0% and 10.0% if not on oral anti-diabetic medications. The trial excludes individuals who use insulin, GLP-1 agonist, or dipeptidyl peptidase-4 (DPP-4) inhibitor, have type 1 diabetes or secondary forms of diabetes, have a major illness with life expectancy less than 5 years, are involved in another study requiring drug therapy, have hypersensitivity to insulin, liraglutide, or metformin, have renal or hepatic dysfunction, have a history of pancreatitis, have a family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma, have a personal history of non-familial medullary thyroid carcinoma, have had malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer), have excessive alcohol consumption, are unwilling to undergo multiple daily insulin injection therapy, have unwillingness to perform capillary blood glucose monitoring at least 4 times per day during intensive insulin therapy, have congestive heart failure, or are pregnant. The trial includes the drug liraglutide and a placebo.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs linagliptin and placebo. The eligibility criteria include being currently treated with a stable dose of metformin and a sulphonylurea drug, having a HbA1c level between 7.0 and 10.0%, being between the ages of 18 and 80, having a BMI of 40 kg/m2 or less, and providing written informed consent. Exclusion criteria include recent myocardial infarction, stroke, or TIA, impaired hepatic or renal function, recent treatment with certain drugs, and known hypersensitivity or allergy to the investigational product or its excipients.",
    "The sample is a clinical trial for a drug called tipranavir, which is being tested on individuals with HIV infections. The trial is in phase 2/phase 3 and the eligibility criteria include being 18 years or older, having completed a previous tipranavir/ritonavir trial or having confirmed virologic failure in previous trials, and having acceptable screening laboratory values indicating adequate baseline organ function. The exclusion criteria include being pregnant or breastfeeding, actively using injection drugs or other substance abuse, having any medical condition that would interfere with participation in the trial, having a history of illness or drug allergy that might confound the results of the study, and having active use of certain medications or herbal medications.",
    "The sample is for a phase 3 clinical trial and includes patients with peripheral neuropathy and HIV infections. The trial involves the drug pregabalin and the eligibility criteria includes having participated in a previous trial and completed it through visit 7. Exclusion criteria includes experiencing a serious adverse event during the previous trial, being non-compliant during the previous trial, and having a clinically significant or unstable medical condition that would compromise participation in the study.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of menorrhagia and heavy menstrual bleeding. The trial includes a list of icd-10 codes for the diseases being studied, as well as a single drug being tested, tranexamic acid tablets (xp12b). The eligibility criteria for the trial include being a woman with menorrhagia, between the ages of 18 and 49, and having regularly occurring menstrual periods. Exclusion criteria include a history or presence of clinically significant disease or abnormalities that might confound the study, as well as a history of bilateral oophorectomy or hysterectomy.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients with a primary diagnosis of Bipolar I Disorder, most recent episode manic or mixed, as defined in the Diagnostic and Statistical Manual of Mental Disorders - Text Revision (DSM-IV TR) and determined by the Mini International Neuropsychiatric Interview (MINI). Patients must have a Young Mania Rating Scale score of 18 or higher at screening and at baseline. They must also be actively receiving lithium or divalproex for their bipolar disorder to be considered for the study. Patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder not otherwise specified (NOS) are excluded from the study. Patients with other DSM-IV-TR Axis I or Axis II disorders in addition to Bipolar I disorder are also ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6-month period prior to screening.",
    "The sample is a phase 3 clinical trial for patients aged 45 and older with established vascular disease and atherogenic dyslipidemia. The trial involves the use of extended release niacin and simvastatin as drugs. The eligibility criteria include specific LDL-C, HDL-C, and TG levels, as well as documented coronary artery disease, cerebrovascular or carotid disease, or symptomatic peripheral arterial disease. The exclusion criteria include recent coronary artery bypass graft surgery, percutaneous coronary intervention, or hospitalization for acute coronary syndrome, as well as certain medical conditions and concomitant use of certain drugs.",
    "This sample is a phase 3 clinical trial for colorectal cancer. The trial is looking for patients who have had a complete resection of their primary tumor within the past 12 weeks and have locally advanced disease. Patients must have received neoadjuvant fluoropyrimidine-based chemoradiotherapy and have no evidence of metastatic disease. The trial is also looking for patients who meet certain patient characteristics, such as having a WHO performance status of 0-1 and no serious uncontrolled medical conditions. Prior concurrent therapy is allowed, but there are restrictions on prior chemotherapy and no prior oxaliplatin. The trial is testing the effectiveness of capecitabine and oxaliplatin as treatment options.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating lymphoma, a type of cancer. The trial includes a list of ICD-10 codes for the disease, a list of drugs being used in the trial, and eligibility criteria for patients to participate. The eligibility criteria include requirements for the patient's age, performance status, life expectancy, and various health factors such as liver and kidney function. The trial also specifies that patients cannot be pregnant, have prior malignancies, or be HIV positive. Finally, the trial notes that patients cannot receive concurrent immunotherapeutic drugs, chemotherapy, or radiotherapy.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of the drug rimonabant (sr141716) and a placebo. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of type 2 diabetes, and being treated with insulin for at least 3 months with an insulin dose of at least 30 U/day for at least 4 weeks. The trial also requires a HbA1C level of greater than or equal to 7%. The exclusion criteria include weight loss of more than 5 kg within 3 months prior to the screening visit, pregnancy or lactation, absence of medically approved contraceptive methods for females of childbearing potential, administration of other investigational drugs within 30 days prior to the screening visit, and previous participation in a Rimonabant study. The trial also excludes patients with any severe medical or psychological condition that would compromise their safety or successful participation in the study, as well as those with a history of cancer within the past 5 years (with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer). The sample also includes exclusion criteria related to laboratory findings and previous or concomitant medications.",
    "The sample is a phase 3 clinical trial for children aged 2 to 10 years with mild or moderate acute flare of dermatitis, atopic. The trial is testing the effectiveness of fluticasone cream compared to a placebo. The eligibility criteria include having a SCORAD score up to 50 and not having received treatment for this episode of AD. Exclusion criteria include having more than 30% of affected body surface area AD, head affected, fluticasone or vehicle allergy, and any medical condition for which topical corticosteroids were contraindicated. Patients with other dermatological conditions that may have prevented accurate assessment of AD, receiving any concomitant medications that might have affected the study's outcome, and other medical history that could interfere with the evaluation of study treatment are also excluded. Patients' parents must provide written informed consent.",
    "The sample is a phase 3 clinical trial for the treatment of mediastinal cancer, metastatic cancer, and testicular germ cell tumor. The trial involves the use of cisplatin, etoposide, and ifosfamide drugs. The eligibility criteria include being a male between the ages of 16 and 50 with a histologically proven germ cell cancer, poor prognosis, and specific tumor markers. Patients must also have a certain performance status, hematopoietic, hepatic, and renal function, and cannot have any other malignancy or serious medical condition. Prior chemotherapy is not allowed, but concurrent radiotherapy and surgery for brain metastases are allowed.",
    "The sample is a record of a clinical trial in phase 3, focused on patients with type 2 diabetes. The trial is testing the effectiveness of the drug vildagliptin in controlling the disease. The eligibility criteria for the trial include patients who have not been able to control their diabetes with diet, exercise, and other medications. Patients must be over 20 years old and have an HbA1c level between 6.5% and 10%. The exclusion criteria include patients with type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes, as well as those with significant heart diseases or diabetic complications.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for allergic rhinoconjunctivitis. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria for the trial include patients experiencing significant allergic symptoms, a medical history of allergic rhinitis and/or rhinoconjunctivitis with clinically relevant sensitization to tree allergens, and specific IgE against birch allergens. The exclusion criteria include a history of significant clinical manifestations of allergy as a result of sensitization against grass or weed pollen and perennial allergens, FEV1 or PEF value \u2264 80 %, and persistent asthma (GINA \u2265 2). There may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a phase 3 trial for the treatment of anxiety disorders using the drugs placebo and quetiapine fumarate xr. The trial includes patients with a documented diagnosis of Generalized Anxiety Disorder who are willing to use a reliable method of birth control and can understand and comply with study requirements. Patients with other psychiatric disorders that could confound the study results, moderate to severe depression, other clinically relevant diseases, or taking certain medications are excluded from the trial. The diseases included in the trial are anxiety, anxiety disorders, anxiety neuroses, and anxiety states, and their corresponding ICD-10 codes are listed.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The trial is testing the effectiveness of the drug goserelin in combination with chemotherapy. The eligibility criteria for the trial includes female patients between the ages of 15 and 46 with pathologically confirmed invasive breast carcinoma and negative hormone-receptor status. Patients must also be premenopausal and willing to use barrier contraception if sexually active. Exclusion criteria includes pregnancy, hypersensitivity to any GnRH analog, and previous receipt of systemic chemotherapy. The trial requires at least four cycles of chemotherapy and a Zubrod performance score of 0 or 1. Platelets must be greater than 50,000/mm^3 and PT and PTT with INR must be less than or equal to 1.5.",
    "The sample is a phase 3 trial for the treatment of insomnia. The trial involves the use of drugs such as 20 mg vec-162, 50 mg vec-162, and 100 mg vec-162, as well as a placebo. The trial includes eligibility criteria for healthy subjects with no medical, psychiatric, or current sleep disorders, who must sign a written consent form. Exclusion criteria include a recent history of night shift work or jet lag, prior experience sleeping in a sleep lab environment, and a history of sleep disorders. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for metastatic castration-resistant prostate cancer. The trial involves the use of drugs such as placebo, abiraterone acetate, and prednisone/prednisolone. The eligibility criteria for the trial include having undergone one or two prior cytotoxic chemotherapies, with at least one containing docetaxel, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 2, and having adequate bone marrow, hepatic, and renal function. The trial also requires participants to have a potassium level of >= 3.5 mmol/L, be able to swallow the study drug whole as a tablet, and provide informed consent. Exclusion criteria include having undergone more than two prior cytotoxic chemotherapy regimens, having a history of pituitary or adrenal dysfunction, and having clinically significant heart disease, among others.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes patients who are 65 years or older and willing to maintain a cholesterol-lowering diet. Patients must have hyperlipidemia with LDL levels greater than 70 mg/dl or 100 mg/dl depending on their CHD risk category. The trial involves the use of drugs such as ezetimibe and atorvastatin, atorvastatin, and a placebo. The eligibility criteria include various inclusion and exclusion criteria, such as the absence of certain medical conditions, compliance with study medication, and laboratory values within certain ranges.",
    "The sample is from a clinical trial in phase 3, which is testing the effectiveness of various drugs, including almorexant, placebo, and zolpidem, on primary insomnia. The trial is looking for adult subjects between the ages of 18 and 64 who have been diagnosed with primary insomnia. The eligibility criteria include not having any other sleep disorders or mental health disorders, not having sleep apnea or restless legs syndrome, not napping for more than an hour per day, and not consuming large amounts of caffeine, tobacco, alcohol, or drugs within the past two years. Additionally, participants must be willing to refrain from taking any medication that affects sleep or behavior.",
    "The sample is a clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial is in phase 2/phase 3 and involves the use of the drugs menatetrenone and placebo. The eligibility criteria include being 20 years or older, having a performance status score of 0-2, and having a diagnosis of hepatocellular carcinoma confirmed through imaging or biopsy. Patients must also have undergone local therapy or surgical treatment within 90 days prior to registration and meet certain liver function criteria. Exclusion criteria include having extrahepatic metastasis or portal invasion, being unable to receive oral administration, and having a history of drug allergy to the study drugs. Women who are pregnant, lactating, or of childbearing potential are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of chronic plaque psoriasis using the drugs apremilast and placebo. The trial includes eligibility criteria for participants, such as being at least 18 years old, having a diagnosis of chronic plaque psoriasis for at least 12 months, and meeting certain laboratory criteria. Exclusion criteria include having other major uncontrolled diseases, being pregnant or breastfeeding, having a history of allergy to any component of the study drug, and having certain infections or skin conditions. Participants must also not have used certain medications or therapies within a certain timeframe prior to randomization. The trial aims to evaluate the effectiveness and safety of apremilast compared to placebo in treating chronic plaque psoriasis.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating pain, nausea, and vomiting in patients with specific diseases, as indicated by their ICD-10 codes. The trial involves the use of two drugs, cl-108 and a placebo. The eligibility criteria for the trial include being likely or possibly nausea-prone, having undergone surgical extraction of at least 2 impacted third molar teeth, and experiencing at least moderate post-operative pain. Exclusion criteria include having a serious medical condition, drug allergies, recent use of an IND drug, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial involves the use of duloxetine hydrochloride and a placebo. The eligibility criteria for the trial include having a previous depressive episode and experiencing painful physical symptoms. However, individuals with anxiety disorders or other psychotic disorders are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of drugs such as tiotropium and olodaterol, as well as a placebo. The eligibility criteria include having a relatively stable airway obstruction, being a current or ex-smoker with a smoking history of more than 10 pack years, and being able to perform technically acceptable pulmonary function tests. Exclusion criteria include having a significant disease other than COPD, clinically abnormal baseline haematology, blood chemistry, or urinalysis, and a history of asthma. Patients who have previously been randomized in this study or are currently participating in another study are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying the effects of buprenorphine and placebo on chronic low back pain. The eligibility criteria include being 18 years or older, having a history of moderate to severe chronic low back pain for at least 3 months, and currently taking a certain amount of oral morphine or another opioid. Exclusion criteria include certain medical conditions and a history of severe emesis with opioids.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying early Parkinson's disease. The icd-10 code for Parkinson's disease is \"G20\". The drugs being tested are \"spm 962\" and \"placebo\". The eligibility criteria for participants include being diagnosed with Parkinson's disease, being between the ages of 30 and 80, having a Hoehn & Yahr stage of 1-3, and having a total sum score of UPDRS Part 2 and 3 over 10 at screening. There are also exclusion criteria, such as having previously participated in a trial with SPM 962, being on L-dopa treatment for over 6 months, having psychiatric symptoms, and having a history of epilepsy or serious cardiac disorder/arrhythmia.",
    "The sample is a phase 3 clinical trial for type 2 diabetes. The trial includes patients who are between 18 and 77 years old, have a BMI of 40 kg/m2 or less, and have been taking metformin immediate release (IR) or XR \u22651500 mg for at least 8 weeks as monotherapy. The trial also requires patients to have a glycosylated hemoglobin (A1C) level between 7% and 10%. The trial excludes women who are pregnant or breastfeeding, women of childbearing potential who are unable or unwilling to use acceptable birth control, patients with significant cardiovascular history, active liver disease, or renal impairment. The trial will test the effectiveness of saxagliptin compared to a placebo.",
    "The sample is a record of a clinical trial in phase 3, focused on chronic obstructive pulmonary disease. The trial includes patients who have had an acute exacerbation and have a pulmonary function test value between 30% and 60% of the predicted normal value. The trial involves the use of two drugs, budesonide/formoterol and prednisolone, and has specific inclusion and exclusion criteria. Patients with a history of asthma, oxygen uptake below 92%, regular use of oxygen therapy, or regular treatment with any inhaled steroid over 1,000 \u00b5g/day at study entry are excluded. Additional inclusion and exclusion criteria will be evaluated by the investigator.",
    "The sample is a phase 3 clinical trial for drug-resistant epilepsy, specifically for partial seizures. The trial is looking for participants between the ages of 18 and 65 who have been diagnosed with epilepsy for more than 2 years and have been treated for more than 1 year with no change in treatment in the month before enrollment. Participants must have experienced a cluster seizure within 24 hours before enrollment. Women must be using effective contraception and be affiliated with the French social security system. The trial is testing the drug levetiracetam. There are several exclusion criteria, including inability to tolerate levetiracetam, taking certain other medications, having certain medical conditions, and being pregnant or nursing. Participants must also be able to give consent and not have suicidal thoughts.",
    "The sample is a phase 3 clinical trial for HIV infection. The trial is testing the drug GW873140. The eligibility criteria for the trial include being HIV-infected with a screening viral load of at least 5000 copies/mL and having a total prior antiretroviral experience of at least 3 months. Participants must also have documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI). Women of childbearing potential must use specific forms of contraception. Exclusion criteria include acute laboratory abnormalities, history of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Participants must be able to receive a ritonavir-boosted protease inhibitor during treatment studies. Additional qualifying criteria and laboratory test requirements will be assessed by the study physician.",
    "The sample is a phase 3 clinical trial for chronic plaque psoriasis. The trial includes patients who have had the disease for at least 6 months and have moderate to severe psoriasis based on PASI, IGA, and body surface area. The patients must also have been inadequately controlled by prior treatments. The trial excludes patients with other forms of psoriasis, drug-induced psoriasis, and those who have used certain drugs in the past. Pregnant or lactating women are also excluded, as well as those with significant medical problems or allergies to rubber or latex. Other inclusion and exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a history of smoking, and have a post-albuterol/salbutamol FEV1/FVC ratio of 0.70 and a post-albuterol/salbutamol FEV1 of >35% and <70% of predicted normal. The trial aims to test the efficacy and safety of several drugs, including gsk573719/gw642444 125/25, gsk573719/gw642444 62.5/25, gsk573719 125, gsk573719 62.5, and gw642444 25. The eligibility criteria include exclusion of patients with asthma, other respiratory disorders, and significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities. The trial also excludes patients who have undergone lung volume reduction surgery within the past 12 months, have a history of drug or alcohol abuse within the past 2 years, or are affiliated with the investigator site.",
    "The sample is a phase 3 clinical trial that involves patients with coronary artery disease, myocardial infarction, and cerebrovascular stroke. The trial includes multiple drugs such as folic acid, vitamin b12 (cyanocobalamin), vitamin b6 (pyridoxine), and placebo. The eligibility criteria for the trial include adults over 18 years of age who are able to give informed consent and prepared to undergo long-term follow-up. Patients with and without significant coronary artery disease who have undergone coronary angiography just before inclusion are also eligible. Exclusion criteria include patients who are not available for follow-up, those who have previously participated in the study, patients with known alcohol abuse or serious mental illness, patients with known active malignant disease, and patients who have undergone coronary angiography for specific reasons.",
    "The sample is a phase 3 clinical trial that focuses on cardiovascular diseases, heart diseases, peripheral vascular diseases, thromboembolism, vascular diseases, and venous thromboembolism. The trial involves the use of warfarin as a drug. The eligibility criteria for the trial include patients with venous thromboembolism, including those with factor V Leiden, who have completed prescribed anticoagulation therapy within the last two years before the trial and are not currently on anticoagulation therapy. The icd-10 codes for the diseases are also provided in the sample.",
    "The sample is a phase 3 clinical trial for patients with pancreatic cancer. The trial includes patients with various stages of the disease and requires documentation of disease extent by CT scan. Patients must not have received prior chemotherapy for metastatic disease and must have evidence of disease progression following adjuvant treatment. The trial allows prior radiation therapy, but at least 4 weeks must have elapsed from completion of the radiation therapy and all signs of toxicity must have resolved. Patients must not have had prior treatment with gemcitabine or bevacizumab in the adjuvant or metastatic setting. The trial also has various eligibility criteria related to cardiovascular disease, recent arterial thrombotic events, CNS disease, active infections, and other factors. Women must be non-pregnant and non-breastfeeding. The trial requires a CT of the abdomen and a chest x-ray as required diagnostic procedures.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being tested (docetaxel, zd4054, and placebo). The eligibility criteria for participants are also listed, including requirements for a confirmed diagnosis of prostate cancer that has spread to the bone, increasing PSA levels, and current treatment with surgical or medical castration. The exclusion criteria are also listed, including previous treatment with certain chemotherapy drugs, recent heart failure or myocardial infarction, and a history of epilepsy or seizures.",
    "The sample is a phase 3 clinical trial for the treatment of post-herpetic neuralgia (PHN) using the drug NGX-4010. The trial includes patients with a diagnosis of PHN and at least 6 months of pain since shingles vesicle crusting. The patients must have intact, unbroken skin over the painful area(s) to be treated and must have average NPRS scores for PHN-associated pain during the screening period of 3 to 9. The trial has inclusion and exclusion criteria, including the exclusion of patients with significant pain of an etiology other than PHN and those with implanted medical devices for the treatment of neuropathic pain. The patients must be willing and able to comply with protocol requirements for the duration of study participation.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients who have not responded to previous therapy with PEGinterferon alpha plus ribavirin. The trial requires patients to have a liver biopsy consistent with a diagnosis of chronic hepatitis C or histological cirrhosis. Patients must also have a wash-out period of at least 6 months from previous therapy with PEGinterferon alpha plus ribavirin. The trial includes both inclusion and exclusion criteria, such as a negative pregnancy test, no use of systemic corticosteroids within 6 months of entry, and no history of severe depression requiring hospitalization or electroshock therapy. The trial also includes a list of drugs being used, including ribavirin and placebo.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on type 2 diabetes mellitus and includes a list of ICD-10 codes for the disease. The trial involves several drugs, including sitagliptin phosphate, glimepiride, and placebos for both drugs. The eligibility criteria for the trial include a diagnosis of type 2 diabetes mellitus, but exclude individuals with a history of type 1 diabetes mellitus, recent surgical procedures, or participation in other studies involving investigational devices or compounds. Other exclusion criteria include hypersensitivity or contraindication to sulfonylurea medication, previous use of dipeptidyl peptidase-4 (DPP-4) inhibitors, presence of HIV, participation in a weight loss program, history of certain cancers or blood disorders, and current or past use of recreational or illicit drugs or alcohol abuse.",
    "The sample is a phase 3 clinical trial for the treatment of B-cell lymphoma. The trial includes patients who are between 18 and 80 years old and have CD20-positive diffuse large B-cell lymphoma. The patients must have low-intermediate, high-intermediate, or high risk disease and/or a bulky tumor with a diameter of at least 7.5 cm. The trial involves the use of bevacizumab, rituximab, chop, and placebo drugs. The eligibility criteria for the trial include Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients who have received prior treatment for diffuse large B-cell lymphoma, have types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL), or have central nervous system (CNS) involvement of lymphoma are excluded from the trial.",
    "The sample is a phase 3 clinical trial for allergic rhinitis. The trial is for male or female subjects between the ages of 4 and 11 who have a documented history of PAR (perennial allergic rhinitis) to a relevant allergen for at least 12 months. The subjects must also have demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test. The trial involves the use of two drugs, bdp nasal aerosol and placebo. The eligibility criteria include various medical conditions and the exclusion criteria include recent respiratory infections or disorders, active asthma requiring treatment, and other clinically significant conditions that may affect the subject's ability to participate in the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of benign prostatic hyperplasia and involves the use of the drugs tadalafil and placebo. The eligibility criteria for the trial include having benign prostatic hyperplasia, providing signed informed consent, and agreeing not to use other treatments for related conditions during the study. Exclusion criteria include having prostatic cancer or being treated for cancer, having certain cardiac conditions or procedures, having very high or low blood pressure, uncontrolled diabetes, or certain problems with the kidneys, liver, or nervous system.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial is looking for patients with locally advanced adenocarcinoma of the prostate who meet certain criteria, including having a Gleason score and PSA known, no bony metastases, and no small cell or transitional cell carcinoma. Patients must also meet certain patient characteristics, such as being under 80 years old and having a life expectancy of at least 5 years excluding malignancy. The trial is testing the effectiveness of several drugs, including bicalutamide, buserelin, flutamide, goserelin, leuprolide acetate, and nilutamide. The eligibility criteria also include prior concurrent therapy and other medical history.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease cystic fibrosis and includes a list of ICD-10 codes associated with the disease. The trial involves the drugs mannitol and placebo. The eligibility criteria for the trial includes a confirmed diagnosis of cystic fibrosis, being over 6 years of age, having a FEV1 between 30% and 90% predicted, and being able to perform all necessary techniques to measure lung function. There are also exclusion criteria, such as being terminally ill or listed for lung transplantation, having had a lung transplant, or having a significant episode of haemoptysis in the three months prior to enrolment. The sample also includes other exclusion criteria related to allergies, intolerances, and other medical conditions that may put the subject at risk or interfere with their participation in the study.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug quetiapine fumarate. The trial is looking for patients who have a documented clinical diagnosis of schizophrenia and are able to understand and comply with the requirements of the study. Patients with a history of non-compliance, a known lack of response to previous treatment with quetiapine, or who have participated in another drug study within 4 weeks prior to enrollment are excluded from the trial. The sample includes the eligibility criteria for both inclusion and exclusion.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have had their tumors completely removed and have no detectable residual axillary disease. The trial includes patients with tumors confined to the breast and axillary nodes, and requires axillary lymph node dissection or a negative axillary sentinel node biopsy. Patients must also have no distant metastases and no locally advanced inoperable breast cancer. Hormone receptor status must be positive for estrogen and/or progesterone, and patients must be premenopausal females. The trial excludes patients with prior ipsilateral or contralateral invasive breast cancer, and those with noncompliance to medical regimens or other nonmalignant systemic diseases that would preclude prolonged follow-up. The trial also excludes patients with psychiatric, addictive, or other disorders that would preclude study compliance. Prior concurrent therapy is allowed for neoadjuvant or adjuvant trastuzumab, but not for neoadjuvant or adjuvant chemotherapy, tamoxifen, other selective estrogen-receptor modulators, hormone replacement therapy, or endocrine therapy since diagnosis of breast cancer. The trial also excludes concurrent oral or transdermal hormonal therapy, other concurrent estrogen, progesterone, or androgens, other concurrent aromatase inhibitors, and concurrent oral or other hormonal contraceptives. The trial requires patients to have no prior bilateral oophorectomy and no concurrent bisphosphonates, except in specific cases.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is looking for male subjects aged between 18 and 80 years old with locally advanced or relapsing prostate cancer following radical prostatectomy or radiotherapy. The trial requires a Gleason score of at least 6 and an ECOG performance status of 0-2. The trial also requires a life expectancy of at least 5 years and two successive decreasing serum PSA levels of less than or equal to 1 ng/ml at randomization. The trial excludes subjects with suspected second primary tumors, evidence of metastatic disease, or any other malignancy within the last 5 years. The trial also excludes subjects with acute spinal cord compression, uni- or bilateral ureteric obstruction, or any concurrent biological response modifier therapy or chemotherapy. Additionally, the trial excludes subjects who have had less than 1 year since any prior neoadjuvant or adjuvant hormonal therapy or less than 6 months since prior 5-alpha reductase inhibitor treatment. The trial also excludes subjects with other concurrent hormonal therapy or any concurrent radiotherapy. The trial requires testosterone at screening to be less than or equal to 1.7 mM or 50 ng/dL and excludes subjects with clinically significant elevation of serum creatinine or liver enzymes or hypersensitivity to GnRH or other GnRH analogues or leuprorelin acetate or CASODEX\u00e2 50 mg.",
    "The sample is a phase 3 clinical trial for bacterial pneumonia. The trial involves the use of drugs such as ceftaroline fosamil for injection, iv ceftriaxone, placebo, and clarithromycin. The eligibility criteria for the trial include having community-acquired pneumonia, requiring initial treatment with IV antimicrobials, and being hospitalized or treated in an emergency room or urgent care setting. Exclusion criteria include having respiratory tract infections not due to community-acquired bacterial, pleural empyema, infection with an atypical organism, and a history of hypersensitivity or allergic reaction to any \u00df-lactam antimicrobial or clarithromycin.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of non-small cell lung cancer. The trial involves the drugs vandetanib and erlotinib. The eligibility criteria for the trial include having confirmed locally advanced or metastatic NSCLC and having failed at least one but not more than two prior chemotherapy regimens. The exclusion criteria include prior treatment with certain drugs such as erlotinib and chemotherapy or other types of anti-cancer therapy within 4 weeks of the study start. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with refractory epilepsy and simple or complex partial onset seizures with or without secondary generalization. The trial is testing the effectiveness of the drug retigabine compared to a placebo. Patients must have a 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase and be currently treated with up to three established AEDs. Vagal Nerve Stimulator may be included. Patients with existing medical or psychiatric conditions that could affect their health or compromise their ability to participate in the study, clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests, impaired renal function, evidence of progressive central nervous disease, lesion, or encephalopathy, history of primary generalized seizures, or history of clustering or flurries or status epilepticus within 12 months of study entry are excluded from the trial.",
    "The sample is a clinical trial for a drug treatment for chronic obstructive pulmonary disease (COPD) in adults aged 40 years and above. The trial is in phase 2/phase 3 and involves several drugs, including indacaterol, formoterol, tiotropium, and placebos. The trial has inclusion criteria such as a smoking history of at least 20 pack years, post-bronchodilator FEV1 < 80% and \u2265 30% of the predicted normal value, and post-bronchodilator FEV1/FVC < 70%. Exclusion criteria include pregnancy or lactation, hospitalization for a COPD exacerbation in the 6 weeks prior to the trial, and a history of asthma or Type I or uncontrolled Type II diabetes. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating non-Hodgkin's lymphoma using a combination of drugs including rituximab, CHOP, and CVP. The eligibility criteria for the trial include patients with previously untreated diffuse large B-cell lymphoma or follicular non-Hodgkin lymphoma, who are at least 18 years old and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients with clinically significant cardiovascular disease or other specific medical conditions are excluded from the trial. The sample also includes a list of disease names, ICD-10 codes, and eligibility criteria.",
    "The sample is a record of a clinical trial in phase 3, which involves patients with acute coronary disease and unstable angina. The trial is testing the effectiveness of two drugs, clopidogrel and acetylsalicyclic acid (ASA), and the eligibility criteria for the trial are listed in the \"criteria\" column. The inclusion criteria require patients to have been diagnosed with acute coronary disease with clinical symptoms and electrocardiogram changes or elevated cardiac enzymes. The exclusion criteria include the use of anticoagulants with an international normalized ratio (INR) greater than 1.5, administration of clopidogrel greater than 75 mg prior to randomization, contraindication to clopidogrel or aspirin, active bleeding, or significant risk of bleeding.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on diabetes and specifically type 2 diabetes. The icd-10 codes associated with the trial include E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are liraglutide, sitagliptin, and metformin. The eligibility criteria for the trial include having type 2 diabetes, being treated with metformin alone for at least three months, having an HbA1c level between 7.5% and 10.0%, having a BMI less than or equal to 45.0, and not having been previously treated with insulin, GLP-1 receptor agonists, or DPP-4 inhibitors. The exclusion criteria include having been treated with anti-diabetic drugs other than metformin within the last three months, having any serious medical condition, and being pregnant, intending to become pregnant, or breastfeeding if female.",
    "The sample is a phase 3 clinical trial for metastatic colorectal cancer. The trial involves the use of drugs such as cediranib, folfox, and xelox, as well as a placebo. The eligibility criteria for the trial include having written informed consent, having carcinoma of the colon or rectum, and having one or more measurable lesions. Exclusion criteria include having received adjuvant/neoadjuvant therapy within 6-12 months of study entry, having untreated unstable brain or meningeal metastases, specific laboratory ranges, specific cardiovascular problems, and participation in other trials within 30 days. The icd-10 codes for the diseases involved in the trial are also provided.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial includes patients with confirmed adenocarcinoma of the prostate who have not received prior cytotoxic chemotherapy and are asymptomatic or mildly symptomatic from prostate cancer. The trial involves a randomized, double-blind treatment period with either enzalutamide or placebo, followed by an open-label treatment period. Eligibility criteria include ongoing androgen deprivation therapy, rising PSA levels or progressive soft tissue or bony disease, and meeting specific inclusion criteria. Exclusion criteria include severe concurrent disease, infection, or co-morbidity, known or suspected brain metastasis or active leptomeningeal disease, and history of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer.",
    "The sample is a phase 3 clinical trial for the treatment of atrial fibrillation. The trial includes patients who have symptomatic AF of 3 to 48 hours duration at baseline and are eligible for cardioversion. The patients must have adequate anticoagulation therapy for cardioversion in accordance with standard of practice as recommended by ACC/AHA/ESC guidelines. The trial excludes patients with known or suspected prolonged QT or uncorrected QT interval of >440 msec, familial long QT syndrome, or previous torsades de pointes, ventricular fibrillation; or sustained ventricular tachycardia (VT). Patients with symptomatic bradycardia, sick sinus syndrome, or ventricular rate less than 50 beats per minute (bpm) are also excluded. Additionally, patients with a QRS interval >140 msec, atrial flutter, significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis, documented previous episodes of second or third degree atrioventricular (AV) block, had a myocardial infarction (MI), acute coronary syndrome or cardiac surgery within 30 days prior to entry into the study, or uncorrected electrolyte imbalance of serum potassium or magnesium are excluded from the trial. The trial will test the effectiveness of vernakalant injection and amiodarone injection as potential treatments for atrial fibrillation.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of pancreatic ductal carcinoma. The trial involves the use of drugs such as ag-013736, gemcitabine, and a placebo. The eligibility criteria for the trial include having confirmed metastatic or locally advanced pancreatic adenocarcinoma, adequate renal, hepatic, and bone marrow function, and a performance status of 0 or 1. Exclusion criteria include prior treatment with any systemic chemotherapy for metastatic disease, prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors, current or recent bleeding or thromboembolic events, and inability to take oral medication.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of saxagliptin compared to a placebo. The eligibility criteria include having type 2 diabetes mellitus, being between the ages of 18-75, and being able to perform blood glucose measurements. Exclusion criteria include having any other form of diabetes, being on more than one blood glucose lowering medication or insulin therapy, having high blood pressure or body mass index, and having certain medical conditions such as liver function test abnormalities or diabetic retinopathy. Patients who are pregnant or breastfeeding, have a history of seizures or epilepsy, or are being treated for severe autoimmune disease are also excluded. The trial is being conducted by AstraZeneca and BMS, and patients must give written consent for their data to be transferred in line with the duty of documentation and notification.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial includes patients aged 18 to 65 who have been diagnosed with overactive bladder and have experienced symptoms for more than 3 months. The symptoms include urinary frequency, urgency, and/or urge incontinence. The trial requires patients to keep a micturition diary card and have a mean volume of single micturition less than 200ml. Patients must also be willing and able to complete the diary card correctly. Exclusion criteria include severe stress incontinence, serious heart disease or arrhythmia, contraindications of anticholinergic therapy, symptomatic acute urinary tract infection, recurrent urinary tract infection, interstitial cystitis, agnogenic hematuria, bladder outlet obstruction of clinical significance, need for retention catheterization or intermittent catheterization, malignant tumor, recent use of anticholinergic drugs or other drugs for treating OAB, pregnancy or lactation, and participation in other clinical trials within 30 days. Women of childbearing age must have taken sufficient contraception measures within 3 months before random number distribution and must not intend to stop the contraception measures during the trial or within one month after the treatment is over.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is testing the effectiveness of carvedilol and valsartan in controlling residual hypertension in patients who are currently on lisinopril monotherapy. The inclusion criteria for the trial is having uncontrolled hypertension with a 24-hour ambulatory diastolic BP >85 mmHg. The exclusion criteria includes a history of serious adverse effects with ACE inhibitor, Coreg, or valsartan, known or suspected causes of secondary hypertension, ischemic heart disease requiring beta-blocker therapy, heart failure, obstructive valvular heart disease or obstructive hypertrophic cardiomyopathy, presence of clinically significant ventricular or supraventricular arrhythmias, chronic kidney disease, uncontrolled diabetes mellitus, history of alcohol or other drug abuse within 6 months prior to enrollment, concomitant treatment or probable need for treatment with prohibited medications, any other medical condition which renders the subject unable to complete the study or which would interfere with optimal participation in the study or produce a significant risk to the subject, persistent systolic BP elevations above 179 mmHg, positive pregnancy test or failure to practice adequate contraception in women of child-bearing potential, bronchospastic asthma requiring chronic steroid or inhaler therapy, and any women with child-bearing potential.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves patients between the ages of 6 and 15 who have been diagnosed with asthma and have received treatment with inhaled corticosteroids within a specified timeframe and dose. The trial excludes patients with severe asthma, those who have received non-inhaled corticosteroids within the previous 4 weeks, those who are sensitive to drugs specified in the protocol, or those who require treatment with beta-blockers. The sample also includes a list of disease names, icd-10 codes, drug names, and eligibility criteria.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drugs sarizotan and placebo in treating Parkinson's disease and dyskinesia. The trial includes patients who have been diagnosed with idiopathic Parkinson's disease and have previously been treated with all registered Parkinsonian medication. The inclusion criteria for the trial include being an out-patient, while the exclusion criteria include being pregnant or lactating (for female subjects), participating in another clinical study within the past 30 days, having received neurosurgical intervention related to PD, having relevant renal or hepatic impairment, suffering from any dementia or psychiatric illness, or having a history of allergic asthma. The diseases being studied are Parkinson's disease and dyskinesia, and their corresponding ICD-10 codes are G20 and K22.4/G24.01, respectively.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a history of smoking, and have a pre and post-albuterol/salbutamol FEV1/FVC ratio of less than 0.70 and a pre and post-albuterol/salbutamol FEV1 of less than or equal to 70% of predicted normal values. The trial involves the use of two drugs, umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg. The eligibility criteria include being an outpatient, providing a signed informed consent, and meeting certain gender and medical history requirements. The trial excludes patients who are pregnant or lactating, have asthma, have other respiratory disorders, have certain medical conditions, or have a history of drug or alcohol abuse.",
    "The sample is a phase 3 clinical trial for participants with type 2 diabetes mellitus who are inadequately controlled with non-insulin antihyperglycemic drugs. The trial involves two drugs, hoe901-u300 and lantus, and has a list of inclusion and exclusion criteria. Inclusion criteria include being an adult with type 2 diabetes mellitus and signing a written informed consent. Exclusion criteria include having an HbA1c level less than 7.0% or greater than 11%, having a history of type 2 diabetes mellitus for less than 1 year before screening, and having received certain medications within a certain time frame before the screening visit. The trial also excludes participants with unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment during the study period.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for the treatment of acute myeloid leukemia. The record includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and the eligibility criteria for participants. The inclusion criteria include having a diagnosis of acute myeloid leukemia, a life expectancy of at least 12 weeks, and signing informed consent. The exclusion criteria include not having acute promyelocytic leukemia, not having any other active systemic malignancies, not having inaspirable bone marrow, not having received previous chemotherapy (except hydroxyurea) for any myeloid disorder, not having chronic respiratory disease that requires continuous oxygen use, not having received any experimental drug within 4 weeks before randomization, not being a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization, and not having known HIV.",
    "The sample is a record of a clinical trial in phase 3, which involves testing drugs for the treatment of endometrial hyperplasia and osteoporosis in postmenopausal women aged 40-75 years with an intact uterus. The trial includes the drugs bazedoxifene/conjugate estrogens (ce), raloxifene, and a placebo. The eligibility criteria for the trial include being generally healthy, having completed the last natural menstrual cycle at least 12 consecutive months before screening, and not having a history or active presence of thrombophlebitis, thrombosis, thromboembolic disorders, cerebrovascular accident, stroke, transient ischemic attack, or malignancy within the previous 10 years. Additional criteria may also apply. The table also includes lists of disease names, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves two drugs, \"duotrav\" and \"cosopt\", which are administered as eye drops. The eligibility criteria for the trial include being 18 years or older and having a diagnosis of glaucoma or ocular hypertension. There are also other protocol-defined inclusion and exclusion criteria that may apply.",
    "The sample is a phase 3 clinical trial for metastatic colorectal cancer. The trial involves the use of oxaliplatin-based chemotherapy, panitumumab, irinotecan-based chemotherapy, and bevacizumab. The eligibility criteria include having adenocarcinoma of the colon or rectum, measurable disease, an ECOG performance status of 0 or 1, and adequate hematologic, renal, and hepatic function. Exclusion criteria include prior chemotherapy or biologic treatment for mCRC disease, major surgery within 28 days before randomization, and preexisting bleeding diathesis or coagulopathy. The trial requires written informed consent and compliance with study requirements.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients with HCV genotype 2 or 3 who have had cirrhosis determination and prior treatment failure. The trial involves the use of drugs such as sof, rbv, placebo to match sof, and placebo to match rbv. The eligibility criteria include screening laboratory values within defined thresholds, no prior exposure to an investigational drug or device within 30 days of the screening visit, and the use of highly effective contraception methods if female of childbearing potential or sexually active male. The exclusion criteria include prior exposure to a direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase, pregnant or nursing female or male with pregnant female partner, current or prior history of clinical hepatic decompensation, history of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol, excessive alcohol ingestion or significant drug abuse.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drugs vortioxetine and placebo. The trial includes eligibility criteria for participants, such as having a Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of 26 or greater and a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater. Exclusion criteria include having previously participated in a Lu AA21004 clinical study, having certain psychiatric or neurological disorders, and having abnormal vital signs or laboratory values. The trial aims to assess the safety, tolerability, and efficacy of the drugs for the treatment of major depressive disorder.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis B. The trial is testing the drug clevudine and has specific eligibility criteria for patients to participate. Inclusion criteria include being between 18 and 60 years old, having HBV DNA levels at screening of at least 3 x 1,000,000 copies/mL, and being HBsAg and HBeAg positive. Exclusion criteria include currently receiving antiviral, immunomodulatory or corticosteroid therapy, having a history of ascites, variceal hemorrhage or hepatic encephalopathy, being co-infected with HCV or HIV, and having evidence of decompensated cirrhosis or hepatocellular carcinoma. Patients must also be willing to use an effective method of contraception during the study and for up to 3 months after the use of the study drug ceases. The sample also includes a list of icd-10 codes for the disease and eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis and pancreatic exocrine insufficiency. The trial involves the use of two drugs, pancrelipase delayed release and a placebo comparator. The eligibility criteria for the trial include confirmed diagnosis of CF and PEI, current treatment with a pancreatic enzyme product, stable body weight, and no evidence of acute respiratory disease or any other acute condition. The exclusion criteria include a history of certain medical conditions, use of immunosuppressive drugs, and any type of malignancy involving the digestive tract in the last 5 years.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for renal transplantation. The diseases column lists only one disease, which is renal transplantation. The icdcodes column contains a list of ICD-10 codes related to the disease. The drugs column lists only one drug, which is fty720. The criteria column contains the eligibility criteria for the trial, including inclusion and exclusion criteria. In this case, the inclusion criteria include patients between 18 to 65 years old who are scheduled to undergo a primary cadaveric or primary non-HLA identical living donor kidney transplantation and have given written informed consent to participate in the study. The exclusion criteria include recipients of multi-organ transplantation or foreseen to receive a non-renal allograft during the study period, graft cold ischemia time greater than 40 hours, and patients with pulse rate < 50 beats per minute (bpm) at screening. Other protocol-defined exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as methotrexate, ocrelizumab, and placebo. The eligibility criteria for the trial include being an adult patient over 18 years of age with active rheumatoid arthritis and inadequate treatment with any DMARD other than methotrexate. The exclusion criteria include having any other rheumatic autoimmune disease or inflammatory joint disease, concurrent treatment with any DMARD other than methotrexate, previous treatment with any cell-depleting therapies, and having had any surgical procedure in the past 12 weeks or planned within 48 weeks after baseline.",
    "This sample is for a phase 3 clinical trial for the treatment of asthma. The trial includes the drug levocetirizine and the eligibility criteria require participants to have completed a previous 18-month treatment period of the EPAAC trial. There are no exclusion criteria listed. The diseases are listed as 'asthma' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for patients with unresectable metastatic colorectal cancer. The trial involves the use of drugs such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria include having histologically confirmed colorectal cancer, measurable disease, and no prior chemotherapy for metastatic disease. Patients must also meet certain physical criteria, such as having a certain level of neutrophils and platelet count, and not having any untreated brain metastases or spinal cord compression. The trial has exclusion criteria, such as having a serious nonhealing wound or ulcer, evidence of bleeding diathesis or coagulopathy, or clinically significant cardiovascular disease. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 3 clinical trial for patients with chronic heart failure and high blood B-type (or brain) natriuretic peptide (BNP) level. The trial includes patients aged between 18 and 85 years who have been hospitalized with a discharge diagnosis of CHF within the previous 3 months before randomization. Patients with functional NYHA class II-IV with LVEF < 40% assessed within the last 3 months and blood BNP levels > 400 pg/ml or NT-ProBNP levels > 1500 pg/ml are also included. The trial aims to test the effectiveness of olmesartan medoxomil + candesartan cilexetil placebo and olmesartan medoxomil placebo + candesartan cilexetil in treating CHF. The eligibility criteria include stable conventional treatment with diuretics, ACEI and/or beta-blockers and/or aldosterone antagonists for at least 2 months prior to randomization, unless documented contraindication or intolerance. The exclusion criteria include patients with current hospitalization due to heart failure, stroke or transient ischemic attack (TIA) within the last 3 months, acute coronary syndrome, myocardial infarction, coronary artery bypass or angioplasty within 3 months, planned cardiac surgery, revascularization or resynchronization within the study period, operable valvular disease or significant obstructive cardiomyopathy, bradycardia (heart rate (HR) < 50 bpm), hypotension (systolic blood pressure (SBP) < 90 mmHg), obstructive pneumopathy, and clinical significant renal failure (creatininemia > 200 micromol/l).",
    "The sample is a phase 3 clinical trial for patients with chronic kidney disease, renal dialysis, and renal insufficiency. The trial is testing the effectiveness of two drugs, asp1585 and sevelamer hydrochloride, in treating hyperphosphatemia. The trial includes patients who have been on a phosphate binder or phosphate lowering drug for 28 days or longer, and have not had a change in dosage within 28 days. Patients must also provide written informed consent. Exclusion criteria include patients with gastrointestinal surgery or enterectomy, severe cardiac diseases, severe constipation or diarrhea, a history or complication of malignant tumors, uncontrolled hypertension, and patients treated with parathyroid intervention.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes. The trial is testing the effectiveness of metformin, ly2189265, and two placebos (oral and subcutaneous) in treating the disease. The eligibility criteria include having type 2 diabetes for at least 3 months but no more than 5 years, being treatment-na\u00efve or taking only one oral antihyperglycemic medication, having a stable weight, and having a BMI between 23 and 45 kg/m^2. Participants must also be willing to perform self-monitored blood glucose testing, learn how to self-inject treatment, and maintain a study diary. Exclusion criteria include having type 1 diabetes, being treated with certain medications, having uncontrolled diabetes that required hospitalization in the past 6 months, and having certain medical conditions or disorders.",
    "The sample is a phase 3 clinical trial for fibromyalgia. The trial includes male and female subjects who are 18 years or older and meet the American College of Rheumatology diagnostic criteria for fibromyalgia. The trial involves the use of two drugs, placebo and xyrem\u00ae, and has eligibility criteria for inclusion and exclusion. Subjects with a history of rheumatic disease or other disorders that may compromise reliable representation of subjective symptoms will be excluded. Additionally, any other condition that may cause a risk to subjects if they participate in the trial is also a reason for exclusion.",
    "The sample is a phase 3 clinical trial that involves patients suffering from Crohn's disease, ulcerative colitis, unclassifiable colitis, or pouchitis, and who need to be treated with corticoids and/or immunosuppressive drugs. The trial aims to test the effectiveness of valganciclovir in treating patients with cytomegalovirus infections. The inclusion criteria require patients to have had a new attack during the three previous months and to be infected with cytomegalovirus. The exclusion criteria include patients with serious or complicated attacks, those suffering from a psychiatric disease or who are uncooperative, those with another serious disease, and those already participating in another clinical trial. The diseases involved in the trial are cytomegalovirus infections and inflammatory bowel diseases, and the icd-10 codes associated with the diseases are provided."
]